POPULARITY
5 episodes with cost plus drugs
2 episodes with cost plus drugs
2 episodes with cost plus drugs
2 episodes with cost plus drugs
2 episodes with cost plus drugs
2 episodes with cost plus drugs
Thursday, March 27th, 2025Today, Jeffrey Goldberg from the Atlantic has released the entire Signal chat except for the name of the CIA agent; the Republican Chair of the Senate Armed Services Committee Wicker and the ranking member Jack Reed have called for an investigation into the Signal chat; a Democrat has won a Pennsylvania State Senate seat for the first time in history; the Supreme Court has upheld Biden's ghost gun limits; an anti-vaxxer has been hired to head a study on vaccines; the Trump administration has responded to Judge Boasberg's order to show cause why they're not in contempt of court for refusing to turn the planes around; Judge Boasberg draws the American Oversight lawsuit against the cabinet members on the Signal chat; and Allison and Dana deliver your Good News.Guest: Mark CubanCost Plus DrugsCost Plus Drugs for BusinessesMark Cuban (@mcuban.bsky.social) — BlueskyThank You, Naked WinesTo get 6 bottles of wine for $39.99, head to nakedwines.com/DAILYBEANS and use code DAILYBEANS for both the code and password.Stories:Atlantic releases transcript of Trump team's Signal chat | The Washington PostVaccine skeptic hired to head federal study of immunizations and autism | The Washington PostDemocrat James Andrew Malone scores an upset win in a Pennsylvania Senate special election | WHTM ABC27Supreme Court Upholds Biden Administration's Limits on ‘Ghost Guns' | The New York TimesGood Trouble: Let's all call and remind our senators who voted for Pete Hegseth that they voted for an unqualified candidate with a questionable background. They put Americans' safety in the hands of an amateur who inexcusably invited a journalist to join an unsecured chat about a foreign military operation. Ask your members of congress to draw up articles of impeachment, and to call on Hegseth, Gabbard, and Ratcliffe to resign immediately. Contacting U.S. Senators | senate.govhttps://5calls.orgTrump and Musk are attempting an illegal power grab is a crisis we must stop. HandsOff2025.comTeslaTakedown — Join the March 29 GLOBAL DAY OF ACTIONFederal workers - feel free to email me at fedoath@pm.me and let me know what you're going to do, or just vent. I'm always here to listen. Share your Good News or Good Trouble:https://www.dailybeanspod.com/good/From The Good NewsLanugo | WikipediaCreation Entertainment's Salute to the Women of Sci-Fi:A Creation Charity Event Give me liberty or give me death! | WikipediaPasadena HumaneTennesseeWilliams.net - HAROLD AND ST. CLAUDETennessee Williams and New Orleans Literary Festival Reminder - you can see the pod pics if you become a Patron. The good news pics are at the bottom of the show notes of each Patreon episode! That's just one of the perks of subscribing! Federal workers - feel free to email me at fedoath@pm.me and let me know what you're going to do, or just vent. I'm always here to listen.Share your Good News or Good Trouble:https://www.dailybeanspod.com/good/ Check out other MSW Media podcastshttps://mswmedia.com/shows/Subscribe for free to MuellerSheWrote on Substackhttps://muellershewrote.substack.comFollow AG and Dana on Social MediaDr. Allison Gill Substack|Muellershewrote, Twitter|@MuellerSheWrote, Threads|@muellershewrote, TikTok|@muellershewrote, IG|muellershewrote, BlueSky|@muellershewroteDana GoldbergTwitter|@DGComedy, IG|dgcomedy, facebook|dgcomedy, IG|dgcomedy, danagoldberg.com, BlueSky|@dgcomedyHave some good news; a confession; or a correction to share?Good News & Confessions - The Daily Beanshttps://www.dailybeanspod.com/confessional/ Listener Survey:http://survey.podtrac.com/start-survey.aspx?pubid=BffJOlI7qQcF&ver=shortFollow the Podcast on Apple:The Daily Beans on Apple PodcastsWant to support the show and get it ad-free and early?Supercasthttps://dailybeans.supercast.com/Patreon https://patreon.com/thedailybeansOr subscribe on Apple Podcasts with our affiliate linkThe Daily Beans on Apple Podcasts
The Hidden Costs of PBMs: How Aggregate Discount Guarantees Inflate Drug Prices. In episode 465 of Relentlessly Seeking Value, host Stacey Richter interviews Chris Crawford, CEO of RxSaveCard, about the inflated costs within the pharmacy benefits industry. The discussion centers around a lawsuit involving J&J, highlighting how large PBMs can significantly overcharge for drugs that are available much cheaper through cash-pay options like Mark Cuban's Cost Plus Drugs. Crawford explains how Aggregate Discount Guarantees, a common contracting mechanism, often fail to control spread pricing effectively and instead may lead to higher costs for plan sponsors and employees. The episode also covers how RxSaveCard can help employers and employees access these lower cash prices, circumventing the inflated costs from traditional PBMs. === LINKS ===
American healthcare is well known for its extreme cost and worst outcomes among industrialized (such as the 38 OECD member) countries, and beyond that to be remarkably opaque. The high cost of prescription drugs contributes, and little has been done to change that except for the government passing the Affordable Insulin Now Act at the end of 2022, enacted in 2023. But in January 2022 Mark Cuban launched Cost Plus Drugs that has transformed how many Americans can get their prescriptions filled at a fraction of the prevailing prices, bypassing pharmacy benefit managers (PBMs) that control 80% of US prescriptions. That was just the beginning of a path of creative destruction (disruptive innovation, after Schumpeter) of many key components American healthcare that Cuban is leading, with Cost Plus Marketplace, Cost Plus Wellness and much more to come. He certainly qualifies as a master disrupter: “someone who is a leader in innovation and is not afraid to challenge the status quo.” Below is a video clip from our conversation dealing with insurance companies. Full videos of all Ground Truths podcasts can be seen on YouTube here. The current one is here. If you like the YouTube format, please subscribe! The audios are also available on Apple and Spotify.Transcript with External links to Audio (00:07):Hello, it's Eric Topol with Ground Truths, and I have our special phenomenal guest today, Mark Cuban, who I think you know him from his tech world contributions and Dallas Mavericks, and the last few years he's been shaking up healthcare with Cost Plus Drugs. So Mark, welcome.Mark Cuban (00:25):Thanks for having me, Eric.Eric Topol (00:27):Yeah, I mean, what you're doing, you've become a hero to millions of Americans getting them their medications at a fraction of the cost they're used to. And you are really challenging the PBM industry, which I've delved into more than ever, just in prep for our conversation. It's just amazing what this group of companies, namely the three big three CVS Caremark, Optum of UnitedHealth and Express Scripts of Cigna with a market of almost $600 billion this year, what they're doing, how can they get away with all this stuff?Inner Workings of Pharmacy Benefit ManagersMark Cuban (01:03):I mean, they're just doing business. I really don't blame them. I blame the people who contract with them. All the companies, particularly the bigger companies, the self-insured companies, where the CEO really doesn't have an understanding of their healthcare or pharmacy benefits. And so, the big PBMs paid them rebates, which they think is great if you're a CEO, when in reality it's really just a loan against the money spent by your sickest employees, and they just don't understand that. So a big part of my time these days is going to CEOs and sitting with them and explaining to them that you're getting ripped off on both your pharmacy and your healthcare side.Eric Topol (01:47):Yeah, it's amazing to me the many ways that they get away with this. I mean, they make companies sign NDAs. They're addicted to rebates. They have all sorts of ways a channel of funds to themselves. I mean, all the things you could think of whereby they even have these GPOs. Each of these companies has a group purchasing organization (I summarized in the Table below).Mark Cuban (02:12):Yeah, which gives them, it's crazy because with those GPOs. The GPO does the deal with the pharmacy manufacturer. Then the GPO also does the deal with the PBM, and then the PBM goes to the self-insured employer in particular and says, hey, we're going to pass through all the rebates. But what they don't say is they've already skimmed off 5%, 10%, 20% or more off the top through their GPO. But that's not even the worst of it. That's just money, right? I mean, that's important, but I mean, even the biggest companies rarely own their own claims data.Mark Cuban (02:45):Now think about what that means. It means you can't get smarter about the wellness of your employees and their families. You want to figure out the best way to do GLP-1s and figure out how to reduce diabetes, whatever it may be. You don't have that claims data. And then they don't allow the companies to control their own formularies. So we've seen Humira biosimilars come out and the big PBMs have done their own version of the biosimilar where we have a product called Yusimry, which is only $594 a month, which is cheaper than the cheapest biosimilar that the big three are selling. And so, you would think in a normal relationship, they would want to bring on this new product to help the employer. No, they won't do it. If the employer asks, can I just add Cost Plus Drugs to my network? They'll say no, every single time.Mark Cuban (03:45):Their job is not to save the employer money, particularly after they've given a rebate. Because once they give that loan, that rebate to the employer, they need to get that money back. It's not a gift. It's a loan and they need to have the rebates, and we don't do rebates with them at all. And I can go down the list. They don't control the formula. They don't control, you mentioned the NDAs. They can't talk to manufacturers, so they can't go to Novo or to Lilly and say, let's put together a GLP-1 wellness program. All these different things that just are common sense. It's not happening. And so, the good news is when I walk into these companies that self-insured and talk to the CEO or CFO, I'm not asking them to do something that's not in their best interest or not in the best interest of the lives they cover. I'm saying, we can save you money and you can improve the wellness of your employees and their families. Where's the downside?Eric Topol (04:40):Oh, yeah. Yeah. And the reason they can't see the claims is because of the privacy issues?Mark Cuban (04:46):No, no. That's just a business decision in the contract that the PBMs have made. You can go and ask. I mean, you have every right to your own claims. You don't need to have it personally identified. You want to find out how many people have GLP-1s or what are the trends, or God forbid there's another Purdue Pharma thing going on, and someone prescribing lots of opioids. You want to be able to see those things, but they won't do it. And that's only on the sponsor side. It's almost as bad if not worse on the manufacturer side.Eric Topol (05:20):Oh, yeah. Well, some of the work of PBMs that you've been talking about were well chronicled in the New York Times, a couple of major articles by Reed Abelson and Rebecca Robbins: The Opaque Industry Secretly Inflating Prices for Prescription Drugs and The Powerful Companies Driving Local Drugstores Out of Business. We'll link those because I think some people are not aware of all the things that are going on in the background.Mark Cuban (05:39):You see in their study and what they reported on the big PBMs, it's crazy the way it works. And literally if there was transparency, like Cost Plus offers, the cost of medications across the country could come down 20%, 30% or more.Cost Plus DrugsEric Topol (05:55):Oh, I mean, it is amazing, really. And now let's get into Cost Plus. I know that a radiologist, Alex Oshmyansky contacted you with a cold email a little over three years ago, and you formed Cost Plus Drugs on the basis of that, right?Mark Cuban (06:12):Yep, that's exactly what happened.Eric Topol (06:15):I give you credit for responding to cold emails and coming up with a brilliant idea with this and getting behind it and putting your name behind it. And what you've done, so you started out with something like 110 generics and now you're up well over 1,200 or 2,500 or something like that?Mark Cuban (06:30):And adding brands. And so, started with 111. Now we're around 2,500 and trying to grow it every single day. And not only that, just to give people an overview. When you go to www.costplusdrugs.com and you put in the name of your medication, let's just say it's tadalafil, and if it comes up. In this case, it will. It'll show you our actual cost, and then we just mark it up 15%. It's the same markup for everybody, and if you want it, we'll have a pharmacist check it. And so, that's a $5 fee. And then if you want ship to mail order, it's $5 for shipping. And if you want to use our pharmacy network, then we can connect you there and you can just pick it up at a local pharmacy.Eric Topol (07:10):Yeah, no, it's transparency. We don't have a lot of that in healthcare in America, right?Mark Cuban (07:15):No. And literally, Eric, the smartest thing that we did, and we didn't expect this, it's always the law of unintended consequences. The smartest thing we did was publish our entire price list because that allowed any company, any sponsor, CMS, researchers to compare our prices to what others were already paying. And we've seen studies come out saying, for this X number of urology drugs, CMS would save $3.6 billion a year. For this number of heart drugs at this amount per year, for chemotherapy drugs or MS drugs this amount. And so, it's really brought attention to the fact that for what PBMs call specialty drugs, whether there's nothing special about them, we can save people a lot of money.Eric Topol (08:01):It's phenomenal. As a cardiologist, I looked up a couple of the drugs that I'm most frequently prescribed, just like Rosuvastatin what went down from $134 to $5.67 cents or Valsartan it went down from $69 to $7.40 cents. But of course, there's some that are much more dramatic, like as you mentioned, whether it's drugs for multiple sclerosis, the prostate cancer. I mean, some of these are just thousands and thousands of dollars per month that are saved, brought down to levels that you wouldn't think would even be conceivable. And this has been zero marketing, right?Mark Cuban (08:42):Yeah, none. It's all been word of mouth and my big mouth, of course. Going out there and doing interviews like this and going to major media, but it's amazing. We get emails and letters and people coming up to us almost single day saying, you saved my grandma's life. You saved my life. We weren't going to be able to afford our imatinib or our MS medication. And it went from being quoted $2,000 a month to $33 a month. It's just insane things like that that are still happening.Eric Topol (09:11):Well, this is certainly one of the biggest shakeups to occur in US healthcare in years. And what you've done in three years is just extraordinary. This healthcare in this country is with its over 4 trillion, pushing $5 trillion a year of expenditure.[New CMS report this week pegs the number at $4.867 trillion for 2023]Mark Cuban (09:30):It's interesting. I think it's really fixable. This has been the easiest industry to the disrupt I've ever been involved in. And it's not even close because all it took was transparency and not jacking up margins to market. We choose to use a fixed margin markup. Some choose to price to market, the Martin Shkreli approach, if you will. And just by being transparent, we've had an impact. And the other side of it is, it's the same concept on the healthcare side. Transparency helps, but to go a little field of pharmacy if you want. The insane part, and this applies to care and pharmacy, whatever plan we have, whether it's for health or whether it's for pharmaceuticals, there's typically a deductible, typically a copay, and typically a co-insurance.Insurance CompaniesMark Cuban (10:20):The crazy part of all that is that people taking the default risk, the credit risk are the providers. It's you, it's the hospital, it's the clinics that you work for. Which makes no sense whatsoever that the decisions that you or I make for our personal insurance or for the companies we run, or if we work for the government, what we do with Medicare or Medicare Advantage, the decisions we all make impacts the viability of providers starting with the biggest hospital systems. And so, as a result, they become subprime lenders without a car or a house to go after if they can't collect. And so, now you see a bunch of people, particularly those under the ACA with the $9,000, the bronze plans or $18,000 out-of-pocket limits go into debt, significant medical debt. And it's unfortunate. We look at the people who are facing these problems and think, well, it must be the insurance companies.Mark Cuban (11:23):It's actually not even the insurance companies. It's the overall design of the system. But underneath that, it's still whoever picks the insurance companies and sets plans that allow those deductibles, that's the core of the problem. And until we get to a system where the providers aren't responsible for the credit for defaults and dealing with all that credit risk, it's almost going to be impossible to change. Because when you see stories like we've all seen in news of a big healthcare, a BUCA healthcare (Blue Cross Blue Shield (BCBS), UnitedHealth, Cigna, and Aetna/CVS) plan with all the pre-authorizations and denials, typically they're not even taking the insurance risk. They're acting as the TPA (third party administrator) as the claims processor effectively for whoever hired them. And it goes back again, just like I talked about before. And as long as CMS hires or allows or accepts these BUCAs with these plans for Medicare for the ACA (Affordable care Act), whatever it may be, it's not going to work. As long as self-insured employers and the 50 million lives they cover hire these BUCAs to act as the TPAs, not as insurance companies and give them leeway on what to approve and what to authorize and what not to authorize. The system's going to be a mess, and that's where we are today.Academic Health System PartnershipsEric Topol (12:41):Yeah. Well, you've been talking of course to employers and enlightening them, and you're also enlightening the public, of course. That's why you have millions of people that are saving their cost of medications, but recently you struck a partnership with Penn Medicine. That's amazing. So is that your first academic health system that you approached?Cost Plus MarketplaceMark Cuban (13:00):I don't know if it was the first we approached, but it was certainly one of the biggest that we signed. We've got Cost Plus Marketplace (CPM) where we make everything from injectables to you name it, anything a hospital might buy. But again, at a finite markup, we make eight and a half percent I think when it's all said and done. And that saves hospital systems millions of dollars a year.Eric Topol (13:24):Yeah. So that's a big change in the way you're proceeding because what it was just pills that you were buying from the pharma companies, now you're actually going to make injectables and you're going to have a manufacturing capability. Is that already up and going?Mark Cuban (13:39):That's all up and going as of March. We're taking sterile injectables that are on the shortage list, generic and manufacturing them in Dallas using a whole robotics manufacturing plant that really Alex created. He's the rocket scientist behind it. And we're limited in capacity now, we're limited about 2 million vials, but we'll sell those to Cost Plus Marketplace, and we'll also sell those direct. So Cost Plus Marketplace isn't just the things we manufacture. It's a wide variety of products that hospitals buy that we then have a minimal markup, and then for the stuff we manufacture, we'll sell those to direct to like CHS was our first customer.Eric Topol (14:20):Yeah, that's a big expansion from going from the pills to this. Wow.Mark Cuban (14:24):It's a big, big expansion, but it goes to the heart of being transparent and not being greedy, selling on a markup. And ourselves as a company, being able to remain lean and mean. The only way we can sell at such a low markup. We have 20 employees on the Cost Plus side and 40 employees involved with the factories, and that's it.Eric Topol (14:46):Wow. So with respect to, you had this phenomenal article and interview with WIRED Magazine just this past week. I know Lauren Goode interviewed you, and she said, Mark, is this really altruistic and I love your response. You said, “how much f*****g money do I need? I'm not trying to land on Mars.” And then you said, “at this point in my life, it's just like more money, or f**k up the healthcare industry.” This was the greatest, Mark. I mean, I got to tell you, it was really something.Mark Cuban (15:18):Yeah.Eric Topol (15:19):Well, in speaking of that, of course, the allusion to a person we know well, Elon. He posted on X/Twitter in recent days , I think just three or four days ago, shouldn't the American people be getting their money's worth? About this high healthcare administration costs where the US is completely away from any other OECD country. And as you and I know, we have the worst outcomes and the most costs of all the rich countries in the world. There's just nothing new here. Maybe it's new to him, but you had a fabulous response on both X and Bluesky where you went over all these things point by point. And of course, the whole efforts that you've been working on now for three years. You also mentioned something that was really interesting that I didn't know about were these ERISA lawsuits[Employee Retirement Income Security Act (ERISA) of 1974.] Can you tell us about that?ERISA LawsuitsMark Cuban (16:13):Yeah, that's a great question, Eric. So for self-insured companies in particular, we have a fiduciary responsibility on a wellness and on a financial basis to offer the members, your employees and their families the best outcomes at the best price. Now, you can't guarantee best outcomes, but you have to be able to explain the choices you made. You don't have to pick the cheapest, but again, you have to be able to explain why you made the choices that you did. And because a lot of companies have been doing, just like we discussed earlier, doing deals on the pharmacy side with just these big PBMs, without accounting for best practices, best price, best outcomes, a couple companies got sued. Johnson and Johnson and Wells Fargo were the first to get sued. And I think that's just the beginning. That's just the writing on the wall. I think they'll lose because they just dealt with the big pharmacy PBMs. And I think that's one of the reasons why we're so busy at Cost Plus and why I'm so busy because we're having conversation after conversation with companies and plenty of enough lawyers for that matter who want to see a price list and be able to compare what they're paying to what we sell for to see if they're truly living up to that responsibility.Eric Topol (17:28):Yeah, no, that's a really important thing that's going on right now that I think a lot of people don't know about. Now, the government of the US think because it's the only government of any rich country in the world, if not any country that doesn't negotiate prices, i.e., CMS or whatever. And only with the recent work of insulin, which is a single one drug, was there reduction of price. And of course, it's years before we'll see other drugs. How could this country not negotiate drugs all these years where every other place in the world they do negotiate with pharma?Mark Cuban (18:05):Because as we alluded to earlier, the first line in every single pharmaceutical and healthcare contract says, you can't talk about this contract. It's like fight club. The number one rule of fight club is you can't talk about fight club, and it's really difficult to negotiate prices when it's opaque and everything's obfuscated where you can't really get into the details. So it's not that we're not capable of it, but it's just when there's no data there, it's really difficult because look, up until we started publishing our prices, how would anybody know?Mark Cuban (18:39):I mean, how was anybody going to compare numbers? And so, when the government or whoever started to negotiate, they tried to protect themselves and they tried to get data, but those big PBMs certainly have not been forthcoming. We've come along and publish our price list and all that starts to change. Now in terms of the bigger picture, there is a solution there, as I said earlier, but it really comes down to talking to the people who make the decisions to hire the big insurance companies and the big PBMs and telling them, no, you're not acting in your own best interest. Here's anybody watching out there. Ask your PBM if they can audit. If you can audit rather your PBM contract. What they'll tell you is, yeah, you can, but you have to use our people. It's insane. And that's from top to bottom. And so, I'm a big believer that if we can get starting with self-insured employers to act in their own best interest, and instead of working with a big PBM work with a pass-through PBM. A pass-through PBM will allow you to keep your own claims, own all your own data, allow you to control your own formulary.Mark Cuban (19:54):You make changes where necessary, no NDA, so you can't talk to manufacturers. All these different abilities that just seem to make perfect sense are available to all self-insured employers. And if the government, same thing. If the government requires pass-through PBMs, the price of medications will drop like a rock.Eric Topol (20:16):Is that possible? You think that could happen?Mark Cuban (20:19):Yes. Somebody's got to understand it and do it. I'm out there screaming, but we will see what happens with the new administration. There's nothing hard about it. And it's the same thing with Medicare and Medicare Advantage healthcare plans. There's nothing that says you have to use the biggest companies. Now, the insurance companies have to apply and get approved, but again, there's a path there to work with companies that can reduce costs and improve outcomes. The biggest challenge in my mind, and I'm still trying to work through this to fully understand it. I think where we really get turned upside down as a country is we try to avoid fraud from the provider perspective and the patient perspective. We're terrified that patients are going to use too much healthcare, and like everybody's got Munchausen disease.Mark Cuban (21:11):And we're terrified that the providers are going to charge too much or turn into Purdue Pharma and over-prescribe or one of these surgery mills that just is having somebody get surgery just so they can make money. So in an effort to avoid those things, we ask the insurance companies and the PBMs to do pre-authorizations, and that's the catch 22. How do we find a better way to deal with fraud at the patient and provider level? Because once we can do that, and maybe it's AI, maybe it's accepting fraud, maybe it's imposing criminal penalties if somebody does those things. But once we can overcome that, then it becomes very transactional. Because the reality is most insurance companies aren't insurance companies. 50 million lives are covered by self-insured employers that use the BUCAs, the big insurance companies, but not as insurance companies.Eric Topol (22:07):Yeah, I was going to ask you about that because if you look at these three big PBMs that control about 80% of the market, not the pass-throughs that you just mentioned, but the big ones, they each are owned by an insurance company. And so, when the employer says, okay, we're going to cover your healthcare stuff here, we're going to cover your prescriptions there.Mark Cuban (22:28):Yeah, it's all vertically integrated.Mark Cuban (22:36):And it gets even worse than that, Eric. So they also own specialty pharmacies, “specialty pharmacies” that will require you to buy from. And as I alluded to earlier, a lot of these medications like Imatinib, they'll list as being a specialty medication, but it's a pill. There's nothing special about it, but it allows them to charge a premium. And that's a big part of how the PBMs make a lot of their money, the GPO stuff we talked about, but also forcing an employer to go through the specialty mail order company that charges an arm and the leg.Impact on Hospitals and ProceduresEric Topol (23:09):Yeah. Well, and the point you made about transparency, we've seen this of course across US healthcare. So for example, as you know, if you were to look at what does it cost to have an operation like let's say a knee replacement at various hospitals, you can find that it could range fivefold. Of course, you actually get the cost, and it could be the hospital cost, and then there's the professional cost. And the same thing occurs for if you're having a scan, if you're having an MRI here or there. So these are also this lack of transparency and it's hard to get to the numbers, of course. There seems to be so many other parallels to the PBM story. Would you go to these other areas you think in the future?Mark Cuban (23:53):Yeah, we're doing it now. I'm doing it. So we have this thing called project dog food, and what it is, it's for my companies and what we've done is say, look, let's understand how the money works in healthcare.Mark Cuban (24:05):And when you think about it, when you go to get that knee done, what happens? Well, they go to your insurance company to get a pre-authorization. Your doctor says you need a knee replacement. I got both my hips replaced. Let's use that. Doctor says, Mark, you need your hips replaced. Great, right? Let's set up an appointment. Well, first the insurance company has to authorize it, okay, they do or they don't, but the doctor eats their time up trying to deal with the pre-authorization. And if it's denied, the doctor's time is eaten up and an assistance's time is eaten up. Some other administrator's time is eaten up, the employer's time is eaten up. So that's one significant cost. And then from there, there's a deductible. Now I can afford my deductible, but if there is an individual getting that hip replacement who can't afford the deductible, now all of a sudden you're still going to be required to do that hip replacement, most likely.Mark Cuban (25:00):Because in most of these contracts that self-insured employers sign, Medicare Advantage has, Medicare has, it says that between the insurance company and the provider, in this case, the hospital, you have to do the operation even if the deductibles not paid. So now the point of all this is you have the hospital in this case potentially accumulating who knows how much bad debt. And it's not just the lost amount of millions and millions and billions across the entire healthcare spectrum that's there. It's all the incremental administrative costs. The lawyers, the benefits for those people, the real estate, the desk, the office space, all that stuff adds up to $10 billion plus just because the hospitals take on that credit default risk. But wait, there's more. So now the surgery happens, you send the bill to the insurance company. The insurance company says, well, we're not going to pay you. Well, we have a contract. This is what it says, hip replacement's $34,000. Well, we don't care first, we're going to wait. So we get the time value of money, and then we're going to short pay you.Mark Cuban (26:11):So the hospital gets short paid. So what do they have to do? They have to sue them or send letters or whatever it is to try to get their money. When we talk to the big hospital systems, they say that's 2%. That's 2% of their revenue. So you have all these associated credit loss dollars, you've got the 2% of, in a lot of cases, billions and billions of dollars. And so, when you add all those things up, what happens? Well, what happens is because the providers are losing all that money and having to spend all those incremental dollars for the administration of all that, they have to jack up prices.Eric Topol (26:51):Yeah. Right.Mark Cuban (26:53):So what we have done, we've said, look for my companies, we're going to pay you cash. We're going to pay you cash day one. When Mark gets that hip replacement, that checks in the bank before the operation starts, if that's the way you want it. Great, they're not going to have pre-authorizations. We're going to trust you until you give us a reason not to trust you. We're not short paying, obviously, because we're paying cash right there then.Mark Cuban (27:19):But in a response for all that, because we're cutting out all those ancillary costs and credit risk, I want Medicare pricing. Now the initial response is, well, Medicare prices, that's awful. We can't do it. Well, when you really think about the cost and operating costs of a hospital, it's not the doctors, it's not the facilities, it's all the administration that cost all the money. It's all the credit risks that cost all the money. And so, if you remove that credit risk and all the administration, all those people, all that real estate, all those benefits and overhead associated with them, now all of a sudden selling at a Medicare price for that hip replacement is really profitable.Eric Topol (28:03):Now, is that a new entity Cost Plus healthcare?Mark Cuban (28:07):Well, it's called Cost Plus Wellness. It's not an entity. What we're going to do, so the part I didn't mention is all the direct contracts that we do that have all these pieces, as part of them that I just mentioned, we're going to publish them.Eric Topol (28:22):Ah, okay.Mark Cuban (28:23):And you can see exactly what we've done. And if you think about the real role of the big insurances companies for hospitals, it's a sales funnel.Getting Rid of Insurance CompaniesEric Topol (28:33):Yeah, yeah. Well, in fact, I really was intrigued because you did a podcast interview with Andrew Beam and the New England Journal of Medicine AI, and in that they talked about getting rid of the insurers, the insurance industry, just getting rid of it and just make it a means test for people. So it's not universal healthcare, it's a different model that you described. Can you go over that? I thought it was fantastic.Mark Cuban (29:00):Two pieces there. Let's talk about universal healthcare first. So for my companies, for our project dog food for the Mark Cuban companies, if for any employee or any of the lives we cover, if they work within network, anybody we have the direct contract with its single-payer. They pay their premiums, but they pay nothing else out of pocket. That's the definition of single-payer.Eric Topol (29:24):Yeah.Mark Cuban (29:25):So if we can get all this done, then the initial single-payers will be self-insured employers because it'll be more cost effective to them to do this approach. We hope, we still have to play it all through. So that's part one. In terms of everybody else, then you can say, why do we need insurance companies if they're not even truly acting as insurance companies? You're not taking full risk because even if it's Medicare Advantage, they're getting a capitated amount per month. And then that's getting risk adjusted because of the population you have, and then there's also an index depending on the location, so there's more or less money that occurs then. So let's just do what we need to do in this particular case, because the government is effectively eliminating the risk for the insurance company for the most part. And if you look at the margins for Medicare Advantage, I was just reading yesterday, it's like $1,700 a year for the average Medicare Advantage plan. So it's not like they're taking a lot of risk. All they're doing is trying to deny as many claims as they can.Eric Topol (30:35):Deny, Deny. Yeah.Mark Cuban (30:37):So instead, let's just get somebody who's a TPA, somebody who does the transaction, the claims processing, and whoever's in charge. It could be CMS, can set the terms for what's accepted and what's denied, and you can have a procedure for people that get denied that want to challenge it. And that's great, there's one in place now, but you make it a little simpler. But you take out the economics for the insurance company to just deny, deny, deny. There's no capitation. There's no nothing.Mark Cuban (31:10):The government just says, okay, we're hiring this TPA to handle the claims processing. It is your job. We're paying you per transaction.Mark Cuban (31:18):You don't get paid more if you deny. You don't get paid less if you deny. There's no bonuses if you keep it under a certain amount, there's no penalties If you go above a certain amount. We want you just to make sure that the patient involved is getting the best care, end of story. And if there's fraud involved as the government, because we have access to all that claims data, we're going to introduce AI that reviews that continuously.Mark Cuban (31:44):So that we can see things that are outliers or things that we question, and there's going to mean mistakes, but the bet was, if you will, where we save more and get better outcomes that way versus the current system and I think we will. Now, what ends up happening on top of that, once you have all that claims data and all that information and everybody's interest is aligned, best care at the best price, no denials unless it's necessary, reduce and eliminate fraud. Once everybody's in alignment, then as long as that's transparent. If the city of Dallas decides for all the lives they cover the 300,000 lives they cover between pharmacy and healthcare, we can usually in actuarial tables and some statistical analysis, we can say, you know what, even with a 15% tolerance, it's cheaper for us just to pay upfront and do this single-pay program, all our employees in the lives we cover, because we know what it's going to take.Mark Cuban (32:45):If the government decides, well, instead of Medicare Advantage the way it was, we know all the costs. Now we can say for all Medicare patients, we'll do Medicare for all, simply because we have definitive and deterministic pricing. Great. Now, there's still going to be outlier issues like all the therapies that cost a million dollars or whatever. But my attitude there is if CMS goes to Lilly, Novo, whoever for their cure for blindness that's $3.4 million. Well, that's great, but what we'll say is, okay, give us access to your books. We want to know what your breakeven point is. What is that breakeven point annually? We'll write you a check for that.Eric Topol (33:26):Yeah.Mark Cuban (33:27):If we have fewer patients than need that, okay, you win. If we have more patients than need that, it's like a Netflix subscription with unlimited subscribers, then we will have whatever it is, because then the manufacturer doesn't lose money, so they can't complain about R&D and not being able to make money. And that's for the CMS covered population. You can do a Netflix type subscription for self-insured employers. Hey, it's 25 cents per month per employee or per life covered for the life of the patent, and we'll commit to that. And so, now all of a sudden you get to a point where healthcare starts becoming not only transparent but deterministic.Eric Topol (34:08):Yeah. What you outline here in these themes are extraordinary. And one of the other issues that you are really advocating is patient empowerment, but one of the problems we have in the US is that people don't own their data. They don't even have all their data. I expect you'd be a champion of that as well.Mark Cuban (34:27):Well, of course. Yeah. I mean, look, I've got into arguments with doctors and public health officials about things like getting your own blood tested. I've been an advocate of getting my own blood tested for 15 years, and it helped me find out that I needed thyroid medication and all of these things. So I'm a big advocate. There's some people that think that too much data gives you a lot of false positives, and people get excited in this day and age to get more care when it should only be done if there are symptoms. I'm not a believer in that at all. I think now, particularly as AI becomes more applicable and available, you'll be able to be smarter about the data you capture. And that was always my final argument. Either you trust doctors, or you don't. Because even if there's an aberrational TSH reading and minus 4.4 and it's a little bit high, well the doctor's going to say, well, let's do another blood test in a month or two. The doctor is still the one that has to write the prescription. There's no downside to trusting your doctor in my mind.Eric Topol (35:32):And what you're bringing up is that we're already seeing how AI can pick up things even in the normal range, the trends long before a clinician physician would pick it up. Now, last thing I want to say is you are re-imagining healthcare like no one. I mean, there's what you're doing here. It started with some pills and it's going in a lot of different directions. You are rocking it here. I didn't even know some of the latest things that you're up to. This seems to be the biggest thing you've ever done.Mark Cuban (36:00):I hope so.Mark Cuban (36:01):I mean, like we said earlier, what could be better than people saying our healthcare system is good. What changed? That Cuban guy.Eric Topol (36:10):Well, did you give up Shark Tank so you could put more energy into this?Mark Cuban (36:16):Not really. It was more for my kids.Eric Topol (36:19):Okay, okay.Mark Cuban (36:20):They go hand in hand, obviously. I can do this stuff at home as opposed to sitting on a set wondering if I should invest in Dude Wipes again.Eric Topol (36:28):Well, look, we're cheering for you. This is, I've not seen a shakeup in my life in American healthcare like this. You are just rocking. It's fantastic.Mark Cuban (36:37):Everybody out there that's watching, check out www.costplusdrugs.com, check out Cost Plus Marketplace, which is business.costplusdrugs.com and just audit everything. What I'm trying to do is say, okay, if it's 1955 and we're starting healthcare all over again, how would we do it? And really just keep it simple. Look to where the risk is and remove the risk where possible. And then it comes down to who do you trust and make sure you trust but verify. Making sure there aren't doctors or systems that are outliers and making sure that there aren't companies that are outliers or patients rather that are outliers. And so, I think there's a path there. It's not nearly as difficult, it's just starting them with corporations, getting those CEOs to get educated and act in their own best interest.Eric Topol (37:32):Well, you're showing us the way. No question. So thanks so much for joining, and we'll be following this with really deep interest because you're moving at high velocity, and thank you.**************************************************Thank you for reading, listening and subscribing to Ground Truths.If you found this fun and informative please share it!All content on Ground Truths—its newsletters, analyses, and podcasts, are free, open-access.Paid subscriptions are voluntary. All proceeds from them go to support Scripps Research. Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. I welcome all comments from paid subscribers and will do my best to respond to each of them and any questions.Thanks to my producer Jessica Nguyen and to Sinjun Balabanoff for audio and video support at Scripps Research.FootnoteThe PBMS (finally) are under fire—2 articles from the past week Get full access to Ground Truths at erictopol.substack.com/subscribe
With the help of co-founder Mark Cuban, Cost Plus Drugs CEO Alex Oshmyansky is radically re-engineering the pharma marketplace and dramatically cutting the price for many prescription drugs. Oshmyansky joins Rapid Response host Bob Safian to share his amazing journey — from struggling as an immigrant in primary school to starting college at age 13, how medical practice led to entrepreneurship, plus reimagining his original plan on advice from the legendary incubator Y Combinator. Oshmyansky explains how Cost Plus Drugs stumbled into success, turning adversaries into allies and harnessing patience as a superpower.For more info, visit: www.rapidresponseshow.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Mark Cuban (entrepreneur, investor, and founder, Cost Plus Drugs) joins Chris Cuomo to discuss disrupting Big Pharma, lowering healthcare costs, and how transparency can fix the system. Cuban also responds to Megyn Kelly's criticism of his political views and shares his thoughts on polarization, ranked choice voting, and why innovation is key to solving America's biggest challenges. Follow and subscribe to The Chris Cuomo Project on Apple Podcasts, Spotify, and YouTube for new episodes every Tuesday and Thursday: https://linktr.ee/cuomoproject Join Chris Ad-Free On Substack: http://thechriscuomoproject.substack.com Support our sponsors: Oracle See if your company qualifies for this special offer at Oracle.com/CCP That's oracle dot com slash CCP. AG1 AG1 is offering new subscribers a FREE $76 gift when you sign up. You'll get a Welcome Kit, a bottle of D3K2 AND 5 free travel packs in your first box. So make sure to check out DrinkAG1.com/ccp to get this offer! Select Quote Get the right life insurance for YOU, for LESS, at SELECT QUOTE DOT COM SLASH CHRISC to get started 120Life For a limited time, Try 120Life and save 20% off. Just use the code “CHRIS20” at checkout at 120life.com Learn more about your ad choices. Visit megaphone.fm/adchoices
With the help of co-founder Mark Cuban, Cost Plus Drugs CEO Alex Oshmyansky is radically re-engineering the pharma marketplace and dramatically cutting the price for many prescription drugs. Oshmyansky joins Rapid Response host Bob Safian to share his amazing journey — from struggling as an immigrant in primary school to starting college at age 13, how medical practice led to entrepreneurship, plus reimagining his original plan on advice from the legendary incubator Y Combinator. Oshmyansky explains how Cost Plus Drugs stumbled into success, turning adversaries into allies and harnessing patience as a superpower.Visit the Rapid Response website here: https://www.rapidresponseshow.com/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
This show from last year was one of the most popular episodes of the past year. And it's also extremely relevant right now, given all of the PBM (pharmacy benefit manager) goings-on, as well as ongoing litigation like the J&J lawsuit, etc. Listen to the show with Julie Selesnick (EP428) for more on that one. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. Also, Brian Reid (EP456) in the episode from a couple of weeks ago. And he talks about how Mark Cuban's way of communicating and framing some of the issues with the big PBMs and just all of the perverse incentives in the drug supply chain. He says this way of communicating is “the chef's kiss.” So, besides the insights here that follow being relevant in and of themselves, there's also some lessons just in how those issues are teed up and communicated that we all can learn from. CEOs and CFOs … hey, this show is for you. Let's start here: What do all of these numbers have in common: $140,000, $3 million, $35 million, and $3 billion? These are all actual examples of how much employers, unions, and some public entities saved on healthcare benefits for themselves and their employees. The roadmap to saving 25% on pharmacy spend and/or 15% on total cost of care in ways that improve employee health and satisfaction always begins when one thing happens. There's one vital first step. That first step is CEOs and/or CFOs or their equivalents roll up their sleeves and get involved in healthcare benefits. Why can't much happen without you, CEOs and CFOs? Here's the IRL: In 2023, the healthcare industry has been financialized. There is a whole financial layer in between your company and its healthcare benefits. And unless the C-suite is involved here and bringing their financial acumen and organizational willpower to the equation, your company and your employees are currently paying hundreds of thousands, maybe millions, of dollars too much and doing so within a business model that deeply exacerbates inequities. There are people out there who are very strategically taking wild advantage of a situation where CEOs/CFOs fear anything to do with healthcare in the title and don't do their normal level of due diligence. You think it's an accident that this whole space got so “complicated”? HR needs your help. Bottom line, if you are a CEO or CFO and you do not know everything that Mark Cuban and Ferrin Williams talk about on the pod today … wow, are you getting shellacked. Mark Cuban uses a different word. Healthcare benefits are, after all, for most companies the second biggest line-item expense after payroll. But don't despair here, because all of this information is really and truly actionable. Others out there are cutting zeros off of their spend and actually doing it in ways that are a total win for employees as well. My guest today, Mark Cuban, is a CEO, after all; and when he looked into it, it took him T-minus ten minutes to figure out just the order of magnitude that his “trusted” benefits consultants and PBM and ASOs (administrative services only) and others were extracting from his business. He pushed back. So can you. But just another reason to dig into that financial layer wrapping around your employee health benefits right now, you might get sued by your employees. Below is an ad currently being circulated on LinkedIn by class action attorneys recruiting employee plan members to sue their employers for ERISA (Employee Retirement Income Security Act of 1974) violations. It's the same attorneys, by the way, from those 401(k) class action lawsuits. I've talked to a few CEOs and CFOs who are scrambling to get ahead of that. You might want to consider doing so as well. Now, for my HR professional listeners, considering that some of what Mark Cuban says in the pod that follows is indeed a little spicy, let me just recognize that the struggle is real. There are multiple competing priorities out there in the real world, for sure. And bottom line, because of those multiple competing priorities out there in the real world, it's really vital that everybody work together up and down the organization in alignment. Lauren Vela talks a lot about these realities here in episode 406. This is a longer show than normal, but it's also like a show and a half. Mark Cuban talks not only about his work with Mark Cuban Cost Plus Drugs, which is a company that buys drugs direct from manufacturers and sells them for cost plus 15%, a dispensing fee, and shipping. It's kind of crazy how so often that price is cheaper, sometimes considerably cheaper, than the price that plan members would have paid using their insurance—and the price that the plan is currently paying the PBM. Most Relentless Health Value Tribe members (ie, regular listeners of this show) will already know that, but what is also fascinating that Mark talks about is what he's doing with his own businesses and the Mavericks on other fronts, like dealing with hospital prices. In this show, we also talk the language of indie pharmacies, fee-only benefits consultants, TPAs (third-party administrators), PBMs, and providers doing direct contracting. There are, in fact, entities out there trying to do the right thing; and Mark acknowledges that. Ferrin Williams, PharmD, MBA, who is also my guest today, is chief pharmacy officer at Scripta and an expert in pharmacy benefits. She adds some great points and some context to this conversation. Scripta is partnering with Mark Cuban Cost Plus Drugs. Scripta has a neat Med Mapper tool and also services to help employees find the lowest costs for their prescriptions. If you are a self-insured employer, for sure, check out Scripta. Here are links to other shows that you should listen to now if you are inspired to take action. I would recommend the shows with Paul Holmes (EP397); Dan Mendelson (EP385); Andreas Mang (EP419); Rob Andrews (EP415); Cora Opsahl (EP372); Lauren Vela (EP406); Peter Hayes (EP346); Gloria Sachdev, PharmD, and Chris Skisak, PhD (EP390); and Mike Thompson (EP389). Also Mark Cuban mentions in this show the beverage distributor L&F Distributors. Thanks to Ge Bai, Andreas Mang, Lauren Vela, Andrew Gordon, Andrew Williams, Cora Opsahl, Kevin Lyons, Pat Counihan, David Dierk, Connor Dierk, John Herrick, Helen Pfister, Kristin Begley, AJ Loiacono, and Joey Dizenhouse for your help preparing for this interview. Also mentioned in this episode are Mark Cuban Cost Plus Drug Company; Scripta Insights; Julie Selesnick; Brian Reid; Paul Holmes; Dan Mendelson; Rob Andrews; Peter Hayes; Gloria Sachdev, PharmD; Chris Skisak, PhD; Mike Thompson; and Scott Conard, MD. You can learn more at Mark Cuban Cost Plus Drug Company and Scripta Insights. You can also connect with Scripta and Ferrin on LinkedIn. Mark Cuban has been a natural businessman since the age of 12. Selling garbage bags door to door, the seed was planted early on for what would eventually become long-term success. After graduating from Indiana University—where he briefly owned the most popular bar in town—Mark moved to Dallas. After a dispute with an employer who wanted him to clean instead of closing an important sale, Mark created MicroSolutions, a computer consulting service. He went on to later sell MicroSolutions in 1990 to CompuServe. In 1995, Mark and longtime friend Todd Wagner came up with an internet-based solution to not being able to listen to Hoosiers basketball games out in Texas. That solution was Broadcast.com—streaming audio over the internet. In just four short years, Broadcast.com (then Audionet) would be sold to Yahoo! Since his acquisition of the Dallas Mavericks in 2000, Mark has overseen the Mavs competing in the NBA Finals for the first time in franchise history in 2006—and becoming NBA World Champions in 2011. Mark first appeared as a “Shark” on the ABC show Shark Tank in 2011, becoming the first ever to live Tweet a TV show. He has been a star on the hit show ever since and is an investor in an ever-growing portfolio of small businesses. Mark is the best-selling author of How to Win at the Sport of Business. He holds multiple patents, including a virtual reality solution for vestibular-induced dizziness and a method for counting objects on the ground from a drone. He is the executive producer of movies that have been nominated for seven Academy Awards: Good Night and Good Luck and Enron: The Smartest Guys in the Room. Mark established Sharesleuth, a research and investigation Web site to uncover fraud in financial markets, and endowed the Electronic Frontier Foundation's Mark Cuban Chair to Eliminate Stupid Patents, an effort to fight patent trolls. Mark gives back to the communities that promoted his success through the Mark Cuban Foundation. The Foundation's AI Bootcamps Initiative hosts free Introduction to AI Bootcamps for low-income high schoolers, starting in Dallas. Mark also saved and annually funds the Dallas Saint Patrick's Day Parade, the largest parade in Dallas and a city institution. In January 2022, he started Mark Cuban Cost Plus Drug Company as an effort to disrupt the drug industry and to help end ridiculous drug prices because every American should have access to safe, affordable medicines. Ferrin Williams, PharmD, MBA, is chief pharmacy officer of Scripta. With 15+ years' experience in the pharmacy industry, Ferrin brings a unique perspective to Scripta that spans the retail pharmacy, pharmacy benefit manager (PBM), and broker/consulting sectors. Her expertise ranges from pharmacy operations and services to innovative clinical programs, pharmacy audit, alternative payer funding, and specialty drugs. As chief pharmacy officer, Ferrin leads the company's clinical strategies organization responsible for devising innovative cost-containment strategies for prescription drugs, ensuring Scripta clients, members, and their providers are provided with best-in-class clinical insights and tools. Ferrin earned her bachelor's, Doctor of Pharmacy, and MBA degrees from the University of Oklahoma. 06:29 What was Mark Cuban's own journey as a self-insured employer with Cost Plus Drug Company? 07:44 What did Mark find when he decided to go through and look through his company's benefit program? 09:12 “When you think it through, you start to realize that money is being spent primarily by your sickest employees.” —Mark 10:02 How do you get CEOs and CFOs of self-insured employers to realize that their sickest employees are the ones subsidizing their checks? 13:00 What is the role of insurance in healthcare? 14:30 “If you can't convince them, confuse them and hide it.” —Mark 15:24 The reality behind getting a rebate check. 16:21 Why are rebates going away, and why isn't that changing PBM earnings? 19:05 How do you get CEOs and CFOs to dig into their benefits plan? 20:59 Does morally abhorrent move the needle? 21:33 “What we're trying to do is just simplify the [healthcare] industry.” —Mark 24:19 What's been changing in consumer behavior? 25:04 “Transparency is a huge part of building that trust.” —Ferrin 25:19 Why CEOs and CFOs really have the power to change healthcare. 32:29 What are Cost Plus Drugs' plans to expand? 39:21 Where is the future of the prescription drug market going? 42:09 What will happen to the prescription drug market in 10 to 20 years? 48:40 The wake-up call self-insured employers should be acknowledging now. 52:02 Where is the real change in the healthcare industry going to come from? You can learn more at Mark Cuban Cost Plus Drug Company and Scripta Insights. You can also connect with Scripta and Ferrin on LinkedIn. @mcuban and Ferrin Williams provide advice for #CEOs and #CFOs of #selfinsuredemployers on our #healthcarepodcast. #healthcare #podcast #digitalhealth #valuebasedcare #healthcareoutcomes Recent past interviews: Click a guest's name for their latest RHV episode! Rob Andrews (Encore! EP415), Brian Reid, Dr Beau Raymond, Brendan Keeler, Claire Brockbank, Cora Opsahl, Dan Nardi, Dr Spencer Dorn (EP451), Marilyn Bartlett, Dr Marty Makary
Ask a Doctor - What Your Doctor Wants You to Know with Dr. Virgie
Mark Cuban - yes, THAT Mark Cuban - uber-successful entrepreneur, NBA team owner, and founder of Cost Plus Drugs company that's disrupting the U.S. pharmaceutical industry, backed an eye-opening study proving the big insider secret behind the 3 simple steps to Crush Medical Debt. You have to hear this one! Also, we're talking about the 3 steps to busting bills people are posting on Buzzfeed. Good stuff! https://crushmedicaldebt.com/
"If my child needs a gene therapy to live, they should get it and anyone's child should. So let's figure out how to pay for it." - Jake Frenz On the final of four podcasts filmed at a recent healthcare thinktank I hosted in Frisco, Texas, Jake Frenz, the founder and CEO of SmithRx, joined me to share his journey from the Marine Corps to Pharmacy Benefit Management, and what makes him so passionate about ending prescription drug price gouging. Jake and I discussed what some of the core challenges are in the PBM space, why he was so inspired by Mark Cuban's venture Cost Plus Drugs, and what the “watershed” moment in US healthcare will look like. I'm grateful to have had the opportunity to talk to one of the best minds in the PBM space, and I hope you enjoy this week's episode of Self-Funded with Spencer. Chapters: 00:00:00 Meet Jake Frenz 00:08:06 Consumer-Driven Healthcare 00:15:53 Transparency in the PBM Industry 00:20:57 The “Watershed Moment” in US Healthcare 00:36:14 Mark Cuban's Innovative Healthcare Venture 00:39:34 Subscription-Based Models Disrupting Pharmacy Competition 00:52:34 Revolutionizing Healthcare 00:55:14 Empowering Americans to Drive Healthcare Reform Key Links for Social: @SelfFunded on YouTube for video versions of the podcast and much more - https://www.youtube.com/@SelfFunded Listen on Spotify - https://open.spotify.com/show/1TjmrMrkIj0qSmlwAIevKA?si=068a389925474f02 Listen on Apple Podcasts - https://podcasts.apple.com/us/podcast/self-funded-with-spencer/id1566182286 Follow Spencer on LinkedIn - https://www.linkedin.com/in/spencer-smith-self-funded/ Follow Spencer on Instagram - https://www.instagram.com/selffundedwithspencer/ Key Words: Healthcare Insights, Pharmacy Benefit Managersm, Simplify Healthcare, Watershed Moment, Cost Plus, cost plus drugs, mark cuban, Big Picture Healthcare, American Spirit, Healthcare Innovation, Affordable Medications, price gouging, self funded, podcast #HealthcareInsights #PharmacyBenefitManagers #SimplifyHealthcare #WatershedMoment #CostPlus #costplusdrugs #markcuban #BigPictureHealthcare #AmericanSpirit #HealthcareInnovation #AffordableMedications #pricegouging #selffunded #podcast --- Support this podcast: https://podcasters.spotify.com/pod/show/spencer-harlan-smith/support
"If my child needs a gene therapy to live, they should get it and anyone's child should. So let's figure out how to pay for it." - Jake Frenz On the final of four podcasts filmed at a recent healthcare thinktank I hosted in Frisco, Texas, Jake Frenz, the founder and CEO of SmithRx, joined me to share his journey from the Marine Corps to Pharmacy Benefit Management, and what makes him so passionate about ending prescription drug price gouging. Jake and I discussed what some of the core challenges are in the PBM space, why he was so inspired by Mark Cuban's venture Cost Plus Drugs, and what the “watershed” moment in US healthcare will look like. I'm grateful to have had the opportunity to talk to one of the best minds in the PBM space, and I hope you enjoy this week's episode of Self-Funded with Spencer. Chapters: 00:00:00 Meet Jake Frenz 00:08:06 Consumer-Driven Healthcare 00:15:53 Transparency in the PBM Industry 00:20:57 The “Watershed Moment” in US Healthcare 00:36:14 Mark Cuban's Innovative Healthcare Venture 00:39:34 Subscription-Based Models Disrupting Pharmacy Competition 00:52:34 Revolutionizing Healthcare 00:55:14 Empowering Americans to Drive Healthcare Reform Key Links for Social: @SelfFunded on YouTube for video versions of the podcast and much more - https://www.youtube.com/@SelfFunded Listen on Spotify - https://open.spotify.com/show/1TjmrMrkIj0qSmlwAIevKA?si=068a389925474f02 Listen on Apple Podcasts - https://podcasts.apple.com/us/podcast/self-funded-with-spencer/id1566182286 Follow Spencer on LinkedIn - https://www.linkedin.com/in/spencer-smith-self-funded/ Follow Spencer on Instagram - https://www.instagram.com/selffundedwithspencer/ Key Words: Healthcare Insights, Pharmacy Benefit Managersm, Simplify Healthcare, Watershed Moment, Cost Plus, cost plus drugs, mark cuban, Big Picture Healthcare, American Spirit, Healthcare Innovation, Affordable Medications, price gouging, self funded, podcast #HealthcareInsights #PharmacyBenefitManagers #SimplifyHealthcare #WatershedMoment #CostPlus #costplusdrugs #markcuban #BigPictureHealthcare #AmericanSpirit #HealthcareInnovation #AffordableMedications #pricegouging #selffunded #podcast --- Support this podcast: https://podcasters.spotify.com/pod/show/spencer-harlan-smith/support
Bakari Sellers is joined by businessman, TV personality, and part owner of the Dallas Mavericks Mark Cuban to discuss the arc of his career (1:04), his transition to pharmaceuticals with his new business Cost Plus Drugs (4:34), and the challenge of raising good kids as a billionaire (13:19). Plus, where he stands on the electoral races in Texas and Massachusetts (15:34), why he supports Kamala Harris for president (26:22), and quick takes on the NBA and WNBA (32:53). Host: Bakari Sellers Guest: Mark Cuban Producer: Donnie Beacham Jr. Executive Producer: Jarrod Loadholt Learn more about your ad choices. Visit podcastchoices.com/adchoices
Entrepreneur, television star, owner of the NBA's Dallas Mavericks, and now PBM disruptor Mark Cuban drops in this week to talk about his newest passion, Cost Plus Drugs, which is turning the industry upside down. Cuban is joined by Cost Plus Drug VP of Pharmacy Relations and Chief Privacy Officer Erin Albert, and well-known industry analyst Antonio Ciaccia. They bat it around with NCPA CEO Douglas Hoey for this very special episode of Independent Rx Forum. https://tccforms.webflow.io/form-one
(0:00) The Besties intro Mark Cuban: Voting record, working with Ross Perot's campaign in 1992 (5:43) The history of Cuban's love/hate relationship with Trump (19:08) Trump's performance as President: what he got right and wrong (40:46) Party nominations: Kamala vs. Trump (49:18) Biden's performance as President: what he got right and wrong (55:45) Should Kamala share blame for Biden's failures? (1:07:01) International conflict, national debt, crypto regulation (1:21:33) General sense of Kamala Harris, why she's been avoiding adversarial interviews, why Sacks supports Trump (1:31:47) Selling a majority of his Mavericks stake, changing business landscape of the NBA, what he's working on at Cost Plus Drugs (1:44:50) Thoughts on AI, what's next for him (1:51:37) Relationship with Elon, re-evaluating the Twitter deal, OpenAI's new fundraise Follow Mark: https://x.com/mcuban Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect Referenced in the show: https://www.eia.gov/dnav/pet/hist/LeafHandler.ashx?n=pet&s=mcrfpus2&f=m https://fred.stlouisfed.org/series/GFDEBTN https://www.architecturaldigest.com/story/wait-are-windowless-bedrooms-going-to-be-a-thing https://washingtonreporter.news/editorial/scoop-kamala-harris-likely-to-nominate-gary-gensler-as-treasury-secretary-if-elected-senate-sources
AFK re-run episode with billionaire Mark Cuban who joins Tyler Ninja Blevins for an in-depth conversation about everything from managing his email deluge and 100+ companies to his Cost Plus Drugs mission and celeb privacy tips. They delve into Mark's NBA ownership, secret hobbies, parenting as a billionaire, and even his favorite splurges. This episode is packed with Mark's insights, humor, and no-holds-barred advice from the one and only maverick mogul. --AFK w/ Ninja is hosted by professional streamer and gamer Tyler "Ninja" Blevins. Join Ninja twice a week as he dives into the internet and the ever changing realms of music, sports, comedy, gaming, and entertainment to uncover the latest projects and excitement brewing within these industries.AFK w/ Ninja drops Tuesdays and Thursdays on Apple Podcasts and everywhere you get your podcast fix.FOLLOW the Official AFK Instagram: @afkwithninjaGRAB some official #TeamNinja merch: teamninja.comHANG with me on more socials: https://pillar.io/ninjaEmail the show at podcast@teamninja.com Produced by SALTExecutive Producer: Nick PanamaCreative Producer: Cameron TaggeAssociate Producer: Andre RojasSound Design & Edit: Aaron Kennedy
In this episode, Scott Becker is joined by Paige Twenter, Assistant Editor at Becker's Healthcare, to discuss the latest in healthcare pricing controversies, Mark Cuban's Cost Plus Drugs initiative, and ongoing drug shortages. Paige provides insights into the pricing debates surrounding GLP-1s, the expansion of affordable drug access, and the critical issue of oncology drug shortages affecting hospitals and patients nationwide.
In this episode, Scott Becker is joined by Paige Twenter, Assistant Editor at Becker's Healthcare, to discuss the latest in healthcare pricing controversies, Mark Cuban's Cost Plus Drugs initiative, and ongoing drug shortages. Paige provides insights into the pricing debates surrounding GLP-1s, the expansion of affordable drug access, and the critical issue of oncology drug shortages affecting hospitals and patients nationwide.
Guest: Mark Cuban, co-founder of Cost Plus Drugs and costar, Shark Tank“I just love to compete,” says Mark Cuban. “And the day I stop is the day I'm dead.” Previously the co-founder of MicroSolutions and Broadcast.com, Cuban is probably best known to the public today for competing with the likes of Daymond John and Barbara Corcoran on the reality TV show Shark Tank. But his real focus — and his real enemy — these days is the pharmaceutical industry. His latest company, Cost Plus Drugs, aims to be far more transparent than established PBMs, or Pharmacy Benefit Managers, and Mark clearly relishes eating their margin. “Everybody talks about disrupting healthcare,” he says. “This is the easiest motherf**king industry I've ever tried to disrupt because it is so opaque, and everybody is so captured by the scale of these big companies.”In this episode, Mark and Joubin discuss Luka Dončić, Synthesia, the Sony hack, the American Dream, TikTok propaganda, MicroSolutions, throwing away watches, keeping kids grounded, Black Mirror, keeping up, Ali Ghodsi, the NBA, MGM, gambling in Dallas, the Adelson family, CES, transparency, and Alex Oshmyansky.Chapters:(00:55) - Game day and superstitions (03:08) - Email responsiveness (05:48) - Shark Tank (09:21) - Retiring young (10:57) - American Airlines' lifetime pass (12:55) - Sports and blue-collar work (16:02) - Compete or die (17:43) - Why Mark hates meetings (19:57) - Immortality through AI (23:05) - The new AI wave (25:07) - Startup founders and low-hanging fruit (29:24) - Selling Broadcast.com to Yahoo (31:35) - The Dallas Mavericks (34:52) - Selling his majority stake (37:08) - The missing link in pharma (41:27) - Disrupting a huge industry (43:57) - The problem with debt (44:59) - What “grit” means to Mark Links:Connect with MarkTwitterLinkedInConnect with JoubinTwitterLinkedInEmail: grit@kleinerperkins.com Learn more about Kleiner PerkinsThis episode was edited by Eric Johnson from LightningPod.fm
April 2, 20224 - Lauren Young joined Byers & Co to talk about their partnership with Mark Cuban's Cost Plus Drugs, Pharmacy Facts with Friends, and their 30% off Spring Sale. Listen to the podcast now!See omnystudio.com/listener for privacy information.
Mark Cuban is a businessman, investor, star of TV series Shark Tank, long-time principal owner of Dallas Mavericks, and founder of Cost Plus Drugs. Please support this podcast by checking out our sponsors: - Listening: https://listening.com/lex and use code LEX to get one month free - Cloaked: https://cloaked.com/lex and use code LexPod to get 25% off - Notion: https://notion.com/lex - Eight Sleep: https://eightsleep.com/lex to get special savings - Shopify: https://shopify.com/lex to get $1 per month trial EPISODE LINKS: Mark's X: https://twitter.com/mcuban Mark's Instagram: https://instagram.com/mcuban Cost Plus Drugs: https://costplusdrugs.com Shark Tank: https://abc.com/shows/shark-tank Dallas Mavericks: https://www.mavs.com PODCAST INFO: Podcast website: https://lexfridman.com/podcast Apple Podcasts: https://apple.co/2lwqZIr Spotify: https://spoti.fi/2nEwCF8 RSS: https://lexfridman.com/feed/podcast/ YouTube Full Episodes: https://youtube.com/lexfridman YouTube Clips: https://youtube.com/lexclips SUPPORT & CONNECT: - Check out the sponsors above, it's the best way to support this podcast - Support on Patreon: https://www.patreon.com/lexfridman - Twitter: https://twitter.com/lexfridman - Instagram: https://www.instagram.com/lexfridman - LinkedIn: https://www.linkedin.com/in/lexfridman - Facebook: https://www.facebook.com/lexfridman - Medium: https://medium.com/@lexfridman OUTLINE: Here's the timestamps for the episode. On some podcast players you should be able to click the timestamp to jump to that time. (00:00) - Introduction (11:10) - Entrepreneurship (26:03) - Shark Tank (36:29) - How Mark made first billion (1:02:39) - Dallas Mavericks (1:08:05) - DEI debate (1:43:58) - Trump vs Biden (1:46:20) - Immigration (1:55:53) - Drugs and Big Pharma (2:11:53) - AI (2:16:05) - Advice for young people
From judging inventions on “Shark Tank” to reshaping the image of NBA ownership, Mark Cuban is known for many things. In this chat with a16z General Partner David Ulevitch, he discusses the importance of entrepreneurship for maintaining America's status as the most innovative place on the planet. This includes making big bets, like he's doing with Cost Plus Drugs, his latest venture that seeks to upend the prescription drug markets. Resources: Find Mark on Twitter: https://twitter.com/mcubanFind David Ulevitch on Twitter: https://twitter.com/daviduLearn more about the American Dynamism Summit: www.a16z.com/ad-summit Stay Updated: Find a16z on Twitter: https://twitter.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Never pay the first bill, at least that's what podcast guest and medical investigative journalist Marshall Allen advises. At some point, every NICU family has to deal with an insurance company, government agency, medical billing office or all three. Learn how to speak a language that billing offices understand, advocate for your rights and save yourself money, headaches and long hours on hold with medical stakeholders.
President Biden calls for expanding the number of drugs Medicare can negotiate prices on. Cigna strikes a deal with drugmakers to cap the cost of popular obesity medications for employer-sponsored health plans. And, Mark Cuban's Cost Plus Drugs inks its first health system partnership. That's coming up on today's episode of Gist Healthcare Daily. Hosted on Acast. See acast.com/privacy for more information.
For a full transcript of this episode, click here. In this healthcare podcast we're talking about pharmacy acronyms or terms like AWP and WAC, and, not really an acronym, but we'll also talk pharmacy list prices, rebates, discounts. We also have NADAC, but that's slightly off to the side for reasons we'll get to in a sec. Most of these acronyms refer to a number with a dollar sign in front of it, and it's hell on wheels to figure out if and/or to what extent that number reflects what is going on in the real world, especially if you are a patient or a plan sponsor and all you see is the list price that Pharma puts out on one side of the storyboard, and then what the patient pays or (if you're lucky) what the plan pays for the drug on the way other side of the whole chain of events. What's a black box a lot of times for patients and plan sponsors is what goes on in the middle, wherein many middle people get their mitts on the transaction. Real quick here, let's run through the Mister Rogers' neighborhood of all of these middle people right now; and we're gonna do this really briefly. Most of you are already going to know most of this, but I just want to remind you so that when my guest today, Luke Slindee, and I kick into the conversation about the acronyms and the terms and we try to follow the dollar … yeah, you can put a name to a face. Alright, so first we have pharma manufacturers. The pharma manufacturer—and this is largely gonna be true whether it's a branded drug or a generic pharma manufacturer—but the manufacturer sets a list price. This list price is gonna be called an AWP or a WAC price, and we're gonna get into the differences and what those terms actually mean in the show that follows. But Pharma decides their price point. They go to wholesalers with that price. Wholesalers say they want a discount to purchase the product. Some kind of rebate or discount is negotiated. Now the wholesalers have the drug, and they get calls from pharmacies. Pharmacies have patients who have scripts for that, so the pharmacies need to buy the drug. What price does the pharmacy now pay the wholesaler for the drug? Short answer: It's nuts. It's nuts how the wholesalers decide what to charge the pharmacies for the drug. We talk about that in the interview that follows, but suffice to say that now we have the list price turning into whatever price the pharmacies wound up paying to get the drug from the wholesalers for. Any way you cut it, the wholesalers are making some money. Okay … now we get to the part where we're figuring out how much the patient or the plan sponsor will pay to pick up that drug that started at the pharma manufacturers and went to the wholesalers and now is at the pharmacy. How much are the patients gonna pay? How much are the plan sponsors gonna pay? If you spend any time in the real world (not the drug supply chain world), what you'd expect to happen next is that the patient would go into the pharmacy and the pharmacist would charge a markup and/or a dispensing fee on the price that they bought the drug from the wholesaler for. That'd be normal. And this can be the case when patients pay cash. Listen to the show with Mark Cuban (EP418, along with Ferrin Williams, PharmD, MBA), who started a pharmacy called Cost Plus Drugs. Get it? Their prices are cost plus. You have had other pharmacies for years doing similar things, like Blueberry in Pittsburgh. They get the drug. They buy it from a wholesaler or etc. But they buy the drug for some price, and then they sell it to their customers (ie, patients) at their cost plus. But most of the time in pharmacy supply chain world, things don't work that way because many patients have insurance. When a patient walks into the pharmacy, someone has to figure out how much the patient owes and how much their insurance will cover, right? So, enter PBMs (pharmacy benefit managers). They originally started out doing this math (ie, adjudicating claims), figuring out what the out-of-pocket will be for the patient and then what the insurance will cover. Then drugs started to get really expensive and a few other developments, and then, all of a sudden, we have PBMs negotiating with Pharma for how much of a rebate the PBM is going to demand for the PBM to put the manufacturer drug on formulary. The PBM also is determining how much they will pay the pharmacy for said drug on behalf of plan sponsors, in addition to doing the math for how much the patient will pay. So, let me say that again because it kind of begs a “what now?” with eyebrows sky-high as the appropriate response to what I just said, especially if you think through the ramifications here, ramifications which I discuss at length with Vinay Patel (EP241); Benjamin Jolley, PharmD (EP422); Scott Haas (EP365); Paul Holmes (EP397); and others. So, again, the PBM is not just adjudicating claims. They are also negotiating rebates from Pharma so plan sponsors do not have to pay the full amount that the wholesalers paid Pharma and that the pharmacies paid the wholesalers, which maybe is a lot of money. The PBMs are like, “Hey, Pharma. You need to give me a piece of your action because we, the PBM, have big market power. I serve 100 million patients or something. So, if you want access to my 100 million lives, you gotta shell it out. You gotta shell me out some rebates.” So, fine, Pharma gives the PBM some amount of money in the form of a rebate. And it has to work that way, if you think about it, because the drug was originally sold to the wholesaler. You see what I'm saying? So, the pharma company has to give the PBMs a separate rebate amount. This is in addition to how much the PBM told the plan sponsor the plan sponsor owes for the drug, which is also paid to the PBM. But now, PBM is also still in charge of adjudicating the claim. So, they're telling the pharmacy how much to charge the patient. Somehow or another also, the PBM also got itself in charge of deciding how much money the pharmacy itself would be reimbursed by that PBM. In the rest of the world, the pharmacy might tell the PBM, “Hey, this is the price.” But not in pharmacy supply chain world. In pharmacy supply chain world, the PBM tells the pharmacy how much it's gonna pay. The end. And this, my friends, is how so often pharmacies get themselves in the pickle of having to pay the wholesaler one price to get the drug while they get reimbursed a totally different price to dispense the drug. And because independents have very little negotiating leverage on actually either side of that equation, they so very often buy high and sell low. Please listen to the shows with Benjamin Jolley (EP422) and Vinay Patel (EP241), where we get into this in a lot of detail. But I just want to emphasize this point: All of that whole drug supply chain I just went through, where the manufacturer sells to the wholesaler who sells to the pharmacy and the PBM pays the pharmacy and the patient is paying something and the plan sponsor is paying something—many of the middleman transactions in there happen under the cover of darkness a lot of times. If I'm a plan sponsor, do I have any idea how much the PBM paid the pharmacy for any particular drug? Unless you're good at looking at the NADAC numbers (more on this coming up), no. I do not have any idea what a fair price for that drug actually is and how much people are making on the back of that drug as it goes through the supply chain. And this, my friends, is how come spread pricing can exist. Because spread pricing is when the PBM charges the plan sponsor more than they are paying the pharmacy, pocketing the difference, and then calling what they pocket a trade secret—even if it's the plan sponsor whose butt is on the line to make sure that what the PBM is pocketing is fair and reasonable compensation. I mean, if only J&J had listened to this show (EP428). Here's a link to the lawsuit, which is about J&J paying ridiculous amounts in spread pricing. If what I just said is really confusing, I'm gonna validate that and say, “Yeah, it is really confusing.” And to a certain extent, that might be the main point. Where there's mystery, there's margin and all of that. Here's what Dawn Cornelis said on LinkedIn in response to an article about the lawsuit: “Data accessibility lies at the heart of mitigating a fiduciary lawsuit. It all begins with gaining access to your data. But let's be clear—it's not an easy feat. The major hurdle? Procuring accurate data from your TPA [third-party administrator]. And that's just the first step. The subsequent challenge involves analyzing this data, a task best handled by a skilled healthcare data analyst—yet another formidable undertaking.” The one acronym in this whole stew that is not questionable at all is the NADAC. So, let's talk about the NADAC for a moment, the National Average Drug Acquisition Cost Price Benchmark. I was really thrilled to get Luke Slindee to be my guest today—or one reason I was so thrilled—is because Luke works for the accounting firm who, on behalf of CMS (Centers for Medicare & Medicaid Services) and the federal government, administers this NADAC, the National Average Drug Acquisition Cost. (Here's a good NADAC explainer if you're interested.) In brief, NADAC was jointly developed by the Centers for Medicare & Medicaid Services, and it calculates the average price that pharmacies pay for prescription drugs. NADAC is based on a retail price survey. My guest today, as aforementioned, is Luke Slindee. He is a second-generation pharmacist. His family owned a pharmacy in Minnesota when he was growing up. Now he is a senior pharmacy consultant for Myers and Stauffer, which is the accounting firm that calculates the NADAC Price Benchmark on behalf of CMS and the federal government. Also mentioned in this episode are Mark Cuban; Ferrin Williams, PharmD, MBA; Blueberry Pharmacy; Vinay Patel; Benjamin Jolley, PharmD; Scott Haas; Paul Holmes; Dawn Cornelis; Capital Rx; Myers and Stauffer LC; Adam Fein; Joey Dizenhouse; Steven Quimby, MD; and Antonio Ciaccia. For additional information, go to data.medicaid.gov. You can also follow Luke on LinkedIn. Luke Slindee, PharmD, is a second-generation pharmacist with a background in independent pharmacy, chain pharmacy, data analytics, and prescription drug pricing. He currently supports public drug pricing transparency benchmarks and is an advocate for pharmacy reimbursement reform and antitrust enforcement in healthcare. 09:52 Why is it important for plan sponsors to understand the going rate for every point in the supply chain? 10:21 How do manufacturers come up with a list price? 10:40 What does AWP stand for? 10:59 What does WAC stand for? 11:06 How are AWP and WAC numbers chosen by the manufacturer? 13:22 What is the difference between AWP and WAC? 14:54 How much are wholesalers paying to manufacturers? 16:43 How much is the pharmacy paying for branded drugs from a wholesaler? 17:34 Why might pharmacies be buying drugs for less than what wholesalers are paying? 18:17 Substack article by Benjamin Jolley, PharmD, on this topic. 19:22 EP423 with Joey Dizenhouse. 20:33 Why do things get weird when a PBM gets involved? 21:58 How does all of this work for generic manufacturers? 25:20 EP344 with Steven Quimby, MD. 26:15 How did Civica Rx come about? 32:21 What's the difference between the NADAC and the AWP value? 36:04 Luke discusses the downstream effects to pharmacies. For additional information, go to data.medicaid.gov. You can also follow Luke on LinkedIn. Luke Slindee discusses #followingthedollar through #WAC, #AWP & #NADAC on our #healthcarepodcast. #healthcare #podcast #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation Recent past interviews: Click a guest's name for their latest RHV episode! Julie Selesnick, Rik Renard, AJ Loiacono (Encore! EP379), Nina Lathia, Marshall Allen, Stacey Richter (INBW39), Peter Hayes, Joey Dizenhouse, Benjamin Jolley, Emily Kagan Trenchard (Encore! EP392)
Stocks fell into the close, ending at session lows. Janus Henderson's Marc Pinto and UBS' Jason Draho break down the market action ahead. After attending a White House roundtable on health care costs, Mark Cuban joins to talk his company Cost-Plus Drugs, regulating AI, if tech stocks are in a bubble and more. Wedbush analyst Matt Bryson breaks down SuperMicro's move higher and what could be next for investors. Cyberark CEO Matt Cohen on the move in cyber stocks. JPMorgan analyst Chris Hovers previews the week ahead in retail earnings.
In this episode of Diabetics Doing Things, Rob interviews Brian Connelly from TheracosBio. Brian shares insights into his background, the mission of Theracos, and their breakthrough SGLT 2 inhibitor, Brenzavvy. The discussion delves into Brian's journey to Theracos, his work in the biotech industry, and the mission of Theracos to provide affordable medications for patients with common diseases, like type 2 diabetes. Topics discussed: 1. Brian Connelly's background and journey to TheracosBio. 2. The mission of TheracosBio to develop affordable medications for patients with chronic diseases. 3. Introduction to Theracos' breakthrough SGLT 2 inhibitor, Brenzavvy. 4. Challenges in the pharmaceutical industry regarding drug pricing and accessibility. 5. Impact of Brenzavvy on patients with type 2 diabetes, focusing on cost, efficacy, and improved health outcomes. 6. Distribution and accessibility of Brenzavvy through Cost Plus Drugs and traditional pharmacies. 7. The importance of alignment within the organization and the societal impact of providing affordable medications. 8. Addressing public health concerns, adherence rates, and long-term cost savings for patients with chronic conditions. Here are key takeaways and lessons: - TheracosBio is dedicated to providing affordable medications, like Brenzavvy, to patients with chronic diseases, such as type 2 diabetes. - Brenzavvy offers cost-effective treatment options with improved health outcomes for patients.- Share struggles to create awareness and support within the community. - The company's mission prioritizes patient access and affordability over maximizing profits, emphasizing societal impact and improved public health. - Collaboration with organizations like Cost Plus Drugs enhances distribution and accessibility of Brenzavvy to a wider patient population. - The importance of transparency, patient feedback, and physician awareness in promoting the use of affordable medications for chronic conditions. References: https://www.theracosbio.com/ https://www.brenzavvy.com 00:00: Unveiling the Noble Mission of TheracosBio: A Journey from Feline Diabetes to Human Therapeutics 05:59: Finding Purpose Through Chronic Illness and Work: A Journey of Passion and Perseverance 13:02: Revolutionizing Drug Pricing: The Mission of Theracos in Making Medication Accessible 19:37: Exploring the High Cost of Diabetes Medication and Solutions 24:28: Addressing Societal Impact and Accessibility in Diabetes Treatment 29:16: Challenges and Misconceptions in the Pharmaceutical Industry 33:45: Building a Mission-Driven Company: The Journey of Theracos CEO 37:57: Revolutionizing Access to Medication: The Success Story of Brenzavvy 40:58: Unveiling Brenzavvy: The Affordable and Effective SGLT 2 Inhibitor for Type 2 Diabetes 45:06: Revolutionizing Healthcare with Low Cost Drugs: A Story of Passion and Purpose
With the MM+M 40 Under 40 event taking place this Thursday, Marc Iskowitz speaks with honoree Jazmin Correa as she recounts her journey from typhoon forecaster in the Peace Corps to CX director at Merck. Lecia Bushak recaps last week's showdown between Sen. Bernie Sanders, (I-VT), and Big Pharma at a Senate hearing. Plus, Jack O'Brien delves into the health ads that ran during Super Bowl LVIII for our Trends segment, along with Mark Cuban's comments about Cost Plus Drugs and the cancer resistance of Chernobyl's mutant wolves. Music by Sixième Son. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.
This is the 25th episode in drug name pronunciation series. First, we talk about three brand-generic drug pairs: Viagra and sildenafil; Cialis and tadalafil; & Levitra and vardenafil. Then, Dr. Erin L. Albert talks about drug pricing with teamcubancard.com and costplusdrugs.com. Erin is a pharmacist and Healthcare Innovator who works for the Mark Cuban Cost Plus Drugs Company as Vice President of Pharmacy Relations. If you're new to my drug name pronunciation series, welcome! In this episode, I divide all six drug names into syllables, tell you which syllables to emphasize, and share the sources of my information. Seeing the written pronunciations can be helpful. All six are below: sildenafil = sil DEN a fil, emphasize DEN Viagra = vi-AG-rah, emphasize AG Tadalafil = ta DA la fil (or my preference ta DAL a fil), emphasize DA or DAL Cialis = see-AL-iss, emphasize AL vardenafil = var-DEN-a-fil, emphasize DEN Levitra = luh-VEE-trah, emphasize VEE Thank you for listening to episode 263 of The Pharmacist's Voice ® Podcast! To read the FULL show notes, visit https://www.thepharmacistsvoice.com/podcast. Select episode 263. Subscribe to or follow The Pharmacist's Voice ® Podcast to get each new episode delivered to your podcast player and YouTube every time a new one comes out! Apple Podcasts https://apple.co/42yqXOG Google Podcasts https://bit.ly/3J19bws Spotify https://spoti.fi/3qAk3uY Amazon/Audible https://adbl.co/43tM45P YouTube https://bit.ly/43Rnrjt Sources All three brand-name drugs have written pronunciations in their package inserts. See section 17: patient information. The following links are from the FDA's website, accessed 2-1-24. Viagra package insert Cialis package insert Levitra package insert The written pronunciations for tadalafil and vardenafil are in the USP Dictionary Online. Sildenafil was not in the USP Dictionary. For the pronunciation of sildenafil, I relied on my experience as a pharmacist and the similarities between sildenafil and vardenafil. Thank you USP Legal Dept for permission to share your written pronunciations in my show notes and YouTube videos! Links from this episode USP Dictionary Online (aka “USAN”) **Subscription-based resource USP Dictionary's (USAN) pronunciation guide (Free resource on the American Medical Association's website) Dr. Erin L. Albert on LinkedIn https://linktr.ee/erinalbert erinalbert.com teamcubancard.com costplusdrugs.com Praise for Dr. Erin L. Albert Erin L. Albert is a unicorn pharmacist, and I look up to her. We met in-person at the 2nd Annual Medipreneurs Summit in Asheville, NC in 2019. She delivered a talk on “Thought Leadership Through Writing and Publishing.” That weekend, Erin suggested I look into starting a podcast. 5 years later, I still remember that conversation like it was yesterday. Thanks Erin! If you're a pharmacist, and you don't know Erin yet, connect with her. She's amazing! You will find the About section from her LinkedIn Profile below (modified to third person on 2-1-24). About Dr. Erin L. Albert Experienced licensed pharmacist, healthcare professional, educator, and attorney with a passion for transformative pharmacy and innovative healthcare solutions. Recognized for achieving substantial cost savings in pharmacy benefits, advocating for transparency, and collaborating with diverse stakeholders. A versatile writer, speaker, and leader with a track record of driving positive change in pharmacy practice, education, and policy. Committed to advancing patient care and promoting excellence in healthcare.
Ask a Doctor - What Your Doctor Wants You to Know with Dr. Virgie
Mark Cuban - yes, THAT Mark Cuban - uber-successful entrepreneur, NBA team owner, and founder of Cost Plus Drugs company that's disrupting the U.S. pharmaceutical industry, backed an eye-opening study proving the big insider secret behind the 3 simple steps to Crush Medical Debt. You have to hear this one! Also, we're talking about the 3 steps to busting bills people are posting on Buzzfeed. Good stuff! https://crushmedicaldebt.com/
Ask a Doctor - What Your Doctor Wants You to Know with Dr. Virgie
Mark Cuban - yes, THAT Mark Cuban - uber-successful entrepreneur, NBA team owner, and founder of Cost Plus Drugs company that's disrupting the U.S. pharmaceutical industry, backed an eye-opening study proving the big insider secret behind the 3 simple steps to Crush Medical Debt. You have to hear this one! Also, we're talking about the 3 steps to busting bills people are posting on Buzzfeed. Good stuff! https://crushmedicaldebt.com/
Ask a Doctor - What Your Doctor Wants You to Know with Dr. Virgie
Mark Cuban - yes, THAT Mark Cuban - uber-successful entrepreneur, NBA team owner, and founder of Cost Plus Drugs company that's disrupting the U.S. pharmaceutical industry, backed an eye-opening study proving the big insider secret behind the 3 simple steps to Crush Medical Debt. You have to hear this one! Also, we're talking about the 3 steps to busting bills people are posting on Buzzfeed. Good stuff! https://crushmedicaldebt.com/
Ask a Doctor - What Your Doctor Wants You to Know with Dr. Virgie
Mark Cuban - yes, THAT Mark Cuban - uber-successful entrepreneur, NBA team owner, and founder of Cost Plus Drugs company that's disrupting the U.S. pharmaceutical industry, backed an eye-opening study proving the big insider secret behind the 3 simple steps to Crush Medical Debt. You have to hear this one! Also, we're talking about the 3 steps to busting bills people are posting on Buzzfeed. Good stuff! https://crushmedicaldebt.com/
241. Myths and Truths - GSM and Pelvic Hormones Thanks to our sponsor Uber Lube 10% off, Code NOTBROKEN uberlube.com Check out my retreat March 2024! https://ascendretreats.com/ Myths about vaginal estrogen What is GSM - genitourinary syndrome of menopause? The original “use it or lose it” paper. Communication in adult sex ed is very important. Non-hormonal options for GSM We discuss vaginal DHEA My opinion about loading doses for vaginal estrogen Hacks to get cheaper vaginal estrogen – Cost Plus Drugs, Good Rx, Amazon Pharmacy Medication options for GSM and why I have a cream bias Access issues for vaginal estrogen When vaginal estrogen doesn't work Why vaginal estrogen is a life long medicine Women post menopause have less estrogen in their bodies than men. Vaginal Estrogen is a preventative medicine. It's role in preventing genitourinary syndrome of menopause. My opinion on the applicator for vaginal estrogen cream. How vaginal estrogen helps overactive bladder symptoms. When our understanding of estrogen is minimal, we don't understand how it affects our overall health. Should we be treating the female partner when we give men Viagra? I discuss the gender bias in treating humans in medicine with aging issues. How can the medical community do better? The problem with the FDA black box warning on the vaginal estrogen product. Is it okay to put estrogen cream on the penis? How to help our kids and the next generation. https://uronurse.com/ Check out details for my retreat: https://ascendretreats.com https://marcella-hill.mystagingwebsite.com/wake-her-up-retreat/ Did you get my “You Are Not Broken” Book Yet? https://amzn.to/3p18DfK Listen to my Tedx Talk: Why we need adult sex ed Join my NEW Adult Sex Ed Master Class: https://www.kellycaspersonmd.com/adult-sex-ed Join my membership to get these episodes ASAP when they are created and without advertisement and even listen live to the interviews and episodes. www.kellycaspersonmd.com/membership --- Send in a voice message: https://podcasters.spotify.com/pod/show/kj-casperson/message
Billionaire Mark Cuban joins Tyler Ninja Blevins for an in-depth conversation about everything from managing his email deluge and 100+ companies to his Cost Plus Drugs mission and celeb privacy tips. They delve into Mark's NBA ownership, secret hobbies, parenting as a billionaire, and even his favorite splurges. This episode is packed with Mark's insights, humor, and no-holds-barred advice from the one and only maverick mogul.Get limited edition AFK Merch now available here!--AFK w/ Ninja is hosted by professional streamer and gamer Tyler "Ninja" Blevins. Join Ninja twice a week as he dives into the internet and the ever changing realms of music, sports, comedy, gaming, and entertainment to uncover the latest projects and excitement brewing within these industries.AFK w/ Ninja drops Tuesdays and Thursdays on Apple Podcasts and everywhere you get your podcast fix.FOLLOW the Official AFK Instagram: @afkwithninjaGRAB some official #TeamNinja merch: teamninja.comHANG with me on more socials: https://pillar.io/ninjaEmail the show at podcast@teamninja.com Produced by SALTExecutive Producers: Nick Panama, Jamie Schefman, and Noah GershCreative Producer: Cameron TaggeAssociate Producer: Andre RojasSound Design & Edit: Aaron Kennedy
Billionaire businessman, TV star & Dallas Mavericks owner, Mark Cuban joins the boys to discuss Jake Paul’s angry 2015 email to him, Logan pitches PRIME, Elon Musk f**king up Twitter, Drake in bed with Bobbi Althoff, Bill Gates pulling his women, MrBeast asking for $1M, downsides of being a billionaire, Kyrie Irving being a “distraction,” Cost Plus Drugs destroying big pharma, Luka or LeBron, why going to college is “dumb” & more… Wear Maverick Clothing ► https://maverickclothing.com SUBSCRIBE TO THE PODCAST ► https://www.youtube.com/impaulsive Tune in to watch the NASCAR Cup Series Playoffs Elimination Race Presented by Xfinity at Martinsville on Sunday October 29th at 2:00 PM Eastern on NBC: https://www.martinsvillespeedway.com/events/2023-fall-cup-race/?cid=MVS_WB_NA_WL_SchedPageFall_220914 https://costplusdrugs.com Watch Previous (Logan Paul on Beating Dillon Danis, KSI Losing vs Tommy Fury, Apologizing to Nina Agdal) ► https://www.youtube.com/watch?v=BTwWAVC0vTg&t=2858s ADD US ON: INSTAGRAM: https://www.instagram.com/impaulsiveshow/ Timestamps: 0:00 Welcome Mark Cuban!
In this episode, we're joined by business magnate and investor Mark Cuban. Cuban describes his journey from humble beginnings as a self-taught programmer to becoming a successful serial entrepreneur and owner of an NBA team. Cuban shares the founding story of his pharmacy benefits company, Cost Plus Drugs, and his vision for reimagining the reimbursement system for care. He also articulates why he believes AI will be more transformative than prior technology shifts such as mobile and the internet and unpacks the potential of AI in addressing previously intractable problems in healthcare. Cuban is a self-made billionaire, bestselling author, star of Shark Tank, and owner of the Dallas Mavericks. Transcript
Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial. Video version: https://www.hcplive.com/view/diabetes-dialogue-implications-of-select-trial-and-brenzavvy-on-cost-plus-drugs
Tune in for today's industry updates.
Mark Cuban (@mcuban) joins Olga Serhiyevich (@olgaserhi), head of investor relations at Village Global, on this episode. Takeaways:- In the US healthcare system the interests of patients, providers, and payers are not aligned. This drives many of the problems in the system today and is part of what inspired Mark to get involved in trying to disrupt the system.- Mark started Cost Plus Drugs to try to address some of the pricing issues with prescription drugs in the US. The company's pricing is completely transparent and shows their costs along with the exact fees they charge. He says that they do zero marketing and their growth comes from earned media and referrals from their existing patient base.- Mark advises founders not to try to optimize the current healthcare system but rather to work outside of the system to bring about real change. Working within the system can bring change around the edges but commits you to working inside a system that is already broken in the hopes that an incumbent player might buy you.- Every pitch deck that Mark sees now has an AI angle to it. He's gone deep on the field over the last several years and says that when a person digs into many of these pitches the companies are using off-the-shelf large language models and have little defensibility.- Precision medicine is one of the most exciting and scary emerging technologies. Mark says that in the next 50-100 years we will be able to compile all the variables that drive how our bodies and minds work and AI will be able to create a precise simulation of our bodies and how to treat them to improve our health.- One of Mark's favourite sayings is that “life is half random.” The conditions around a person are continually changing and contribute greatly to a person's success.Thanks for listening — if you like what you hear, please review us on your favorite podcast platform.Check us out on the web at www.villageglobal.vc or get in touch with us on Twitter @villageglobal.Want to get updates from us? Subscribe to get a peek inside the Village. We'll send you reading recommendations, exclusive event invites, and commentary on the latest happenings in Silicon Valley. www.villageglobal.vc/signup
Our guest on this episode is Mark Cuban. In addition to a storied business career that includes owning the NBA's Dallas Mavericks and a role on ABC's Shark Tank, Mark is the founder and lead investor in the Mark Cuban Cost Plus Drug Company, a generic pharmaceutical distributor that prices medications at cost, plus a 15% administrative markup and any relevant pharmacy and shipping fees. Founded in early 2022, over 1.7M patients have signed up for the service in their first year, and Cost Plus Drugs now offers over 1,000 generic medications for purchase on their website. Mark founded the company with CEO Dr. Alex Oshmyansky, a pediatric radiologist who originally tried to start an organization similar to Cost Plus Drugs as a non-profit, before pivoting and convincing Mark to be his partner. In this episode, I spoke with Mark about: His journey to starting Cost Plus Drugs How the company is able to drive down prices so drastically compared to the existing players How incumbents, such as traditional pharmacy benefit managers and new entrants, such as the Amazon RxPass, will impact the success of Cost Plus Drugs
So far it doesn't look promising for the irritable entrepreneur and his "Cost Plus Drugs. The idea was to sell generics at a discount but the products are already sold at rock bottom prices. Better costs can sometimes be found at your local pharmacy and customer service seems to be lacking. Contact me at: DBJ@MLMMailbag.com (Most severe critic: A+) Inspired by: "MEDICARE FOR THE LAZY MAN 2023; Simplest & Easiest Guide Ever!" on Amazon.com. Return to leave a short customer review & help future readers. Official website: https://www.MedicareForTheLazyMan.com
Dr. Maxwell Cooper is a resident physician training in diagnostic and interventional radiology at Emory University in Atlanta, GA. He is the Host of The DaVinci Hour Podcast where he interviews a variety of guests making an impact on healthcare, including Mark Cuban discussing his low-cost pharmacy business Cost Plus Drugs. Dr. Cooper is also the Co-Founder of DaVinci Academy, a company that provides video courses on YouTube, digital textbooks, and podcasts for medical students. We talked about how he developed these courses while he was a med student. In addition to podcasting and medical education, Dr. Cooper is also passionate about medical device development and is currently part of a team of interventional radiologists at Emory and engineers at Georgia Tech working on an early-stage dialysis access monitoring device. We also talked about what he learned about device development like securing financing, intellectual property, and interacting with engineers. You can find his courses and podcast at https://www.dviacademy.com/ and you can find him on linkedin and Instagram @maxwellcooperMD
Keaton and Evan hit the ground running by breaking down how out of touch some influencers are. Cost + Drugs is saving people tons of money and you should be taking advantage of it. ( costplusdrugs.com ) Cost plus drugs tik tok video: https://www.tiktok.com/t/ZTRGUsNyh/ Twitter: https://twitter.com/simply_technicl Facebook: https://www.facebook.com/simplytechnicl/ Instagram: https://www.instagram.com/simply_technicl/ Intro/Outro Song: Suburbs by Nick Midnight https://music.apple.com/us/album/suburbs/1318520299?i=1318520676
In this month's episode of Tuning In to the C-Suite, Managing Editor Peter Wehrwein talks with Rick Bates, MBA, president and CEO of RxSense. In his conversation with Wehrwein, Bates described RxSense as a “technology platform company that has expertise in the direct-to-consumer business.” He emphasized that RxSense is not a pharmacy benefit manager (PBM) — but, rather, a company that supplies PBMs with technology, including some of the up-and-coming PBMs, such as EmsanaRx and Vivid Clear Rx. Bates and Wehrwein also discussed the Mark Cuban Cost Plus Drug and RxSense launching a standalone business intelligence product called Rx IQ.
Mark Cuban, one of America's most famous and successful entrepreneurs, recently launched a new drug company - Cost Plus Drugs - that is disrupting the healthcare industry and significantly reducing the cost of prescription drugs for millions of Americans. In this episode, he extols the virtues of a capitalist system that is able to identify and provide real world solutions to problems that are often ignored by government agencies. Mark also shares his thoughts on the risk of a recession in 2023, how AI and ChatGPT could displace millions of knowledge workers, Elon Musk's takeover of twitter, and why billionaires like himself are often demonized by politicians like Elizabeth Warren and Alexandria Ocasio-Cortez. The host of the Munk Debates is Rudyard Griffiths - @rudyardg. Tweet your comments about this episode to @munkdebate or comment on our Facebook page https://www.facebook.com/munkdebates/ To sign up for a weekly email reminder for this podcast, send an email to podcast@munkdebates.com. To support civil and substantive debate on the big questions of the day, consider becoming a Munk Member at https://munkdebates.com/membership Members receive access to our 10+ year library of great debates in HD video, a free Munk Debates book, newsletter and ticketing privileges at our live events.This podcast is a project of the Munk Debates, a Canadian charitable organization dedicated to fostering civil and substantive public dialogue - https://munkdebates.com/ Senior Producer: Ricki Gurwitz
Cost Plus Drugs Co-founder Mark Cuban | Full Interview | Cost Plus Drugs Co-founder Mark Cuban sits down with Kara Swisher at the 2022 Code Conference.
Billionaire Mark Cuban never holds back his opinions on TV's “Shark Tank” and now he's trying to take a bite out of the health care sector — it might be his biggest challenge yet. Cuban understands he's up against entrenched lobbyists and bureaucrats as he tries to reform how Americans purchase their pharmaceuticals. Hosts Mark Masselli and Margaret Flinter ask Cuban to explain his venture Cost Plus Drugs, its financial model and how some insurers are already joining in. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/
The big three healthcare companies aren't paying much attention to Mark Cuban's new health care venture, Cost Plus Drugs. But their margins could mean a huge opportunity for the new start-up. Chris Hill caught up with Cuban to discuss: - Why he's able to sell a leukemia drug for thousands of dollars less than competitors - Stocks he bought during the pandemic - Advice for potential NFL owner Jeff Bezos To check out Mark's new business go to www.CostPlusDrugs.com Companies mentioned: WBA, CVS, NFLX, LYV, LVS, AMZN Host: Chris Hill Guest: Mark Cuban Producer: Ricky Mulvey Engineers: Dan Boyd, Austin Morgan, Tim Sparks
Billionaire Mark Cuban never holds back his opinions on TV's “Shark Tank” and now he's trying to take a bite out of the health care sector — it might be his biggest challenge yet. Cuban understands he's up against entrenched lobbyists and bureaucrats as he tries to reform how Americans purchase their pharmaceuticals. Hosts Mark Masselli and Margaret Flinter ask Cuban to explain his venture Cost Plus Drugs, its financial model and how some insurers are already joining in.
Billionaire Mark Cuban never holds back his opinions on TV's “Shark Tank” and now he's trying to take a bite out of the health care sector — it might be his biggest challenge yet. Cuban understands he's up against entrenched lobbyists and bureaucrats as he tries to reform how Americans purchase their pharmaceuticals. Hosts Mark Masselli and Margaret Flinter ask Cuban to explain his venture Cost Plus Drugs, its financial model and how some insurers are already joining in. The post What Does Shark Tank's Mark Cuban Know About Fixing Health Care? Are There Lessons for All of Us? appeared first on Healthy Communities Online.
Rising drug prices have been a constant fixture in the news. The absurd prices of some critical medicines have left people with a choice between rent or survival. But that is beginning to change. Mark Cuban's entry into the market with Cost Plus Drugs has gotten a lot of press, but did you know that there is another option. We are talking with a company that is looking to take on Cost Plus with deeper discounts and a larger catalogue.Today we are talking with Satish Srinivasan, CEO or DiRx. DiRx is an online pharmacy that is looking to make prescriptions more affordable. Most importantly, they are pushing the industry to do more for under-insured and uninsured Americans with dependable, year-round access to their life-saving medications at a consistent price point.Most recently, they debuted their Annual Savings Plan which provides customers with access to an unlimited amount of generic prescriptions for as low as $10-25 total per month.So let's talk with Satish about how they make it all work.Welcome SatishClick Here to SubscribeFUTR.tv focuses on startups, innovation, culture and the business of emerging tech with weekly podcasts featuring Chris Brandt and Sandesh Patel talking with Industry leaders and deep thinkers.Occasionally we share links to products we use. As an Amazon Associate we earn from qualifying purchases on Amazon.
See our hour-long program with Mark Cuban at WCBS880.com.
Mark Cuban joins us to talk about the Dallas Mavericks, Cost Plus Drugs, and Shark Tank!
It's It's “In the News…” a look at the top diabetes stories and headlines of the past seven days. This week: Provention Bio hopes to get FDA approval of Teplizumab next month and partners with Sanofi on this T1D prevention drug, new type 2 studies show that younger people who develop it generally have worse health outcomes, Medicare considers expanded coverage of CGMs and more Learn more about the T1D Exchange: www.T1Dexchange.org/Stacey Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Provention Bio partners with Sanofi to help bring teplizumab to market. Teplizumab isn't yet approved, the FDA is expected to give it the thumbs up later this year.. this is the drug shown to prevent type 1 diabetes for up to three years. Among other things, Sanofi will get exclusive global marketing rights for the drug. The FDA had asked for more information the last time teplizumab was up for approval.. the three month period for that closes in November.. and a ruling is expected then. https://www.fiercepharma.com/pharma/proventions-regulatory-odyssey-diabetes-nears-its-end-company-taps-sanofi-marketing-assist XX New research has found that the age at which people are diagnosed with type 2 diabetes is associated with a higher risk of developing serious complications. The study, which was published in JAMA Network Open, analyzed health data from more than 36,000 Americans aged 50 and above. The researchers found that those who were diagnosed with type 2 diabetes between the ages of 50 and 59 had “elevated risks” of heart disease, stroke, disability, cognitive impairment, and early death. But when people were diagnosed with diabetes later in life, the risks were reduced.1 No obvious reason for that.. but the researchers say it does point to the need for more screening and better prevention and treatment. https://www.verywellhealth.com/type-2-diabetes-diagnosis-age-6747897 XX The Centers for Medicare and Medicaid Services has proposed new draft coverage guidelines for continuous glucose monitors. Under the proposal, the CMS would cover CGMs for diabetes patients who are treated with insulin or “have a history of problematic hypoglycemia,” as defined by the frequency or severity of low blood sugar events, seemingly regardless of whether they have Type 1 or 2 diabetes. Analysts at J.P. Morgan said the proposal reads “very favorably” for Abbott and Dexcom, leading CGM manufacturers that are targeting the “massive and highly under-penetrated Type 2 market opportunity.” https://www.medtechdive.com/news/dexcom-abbot-CGM-diabetes-coverage/633577/ XX Mark cuban's Cost Plus Drugs has joined with @RocheDiabetesUS to provide our patients with their line of Accu-ChekⓇ test strips, lancets, & meters! This partnership will allow anyone to access what they need to check their blood sugar, at a low price. XX Researchers who study Type 2 diabetes have reached a stark conclusion: There is no device, no drug powerful enough to counter the effects of poverty, pollution, stress, a broken food system, cities that are hard to navigate on foot and inequitable access to health care, particularly in minority communities. This is a long and complicated article published in the New York Times.. I'll link it up and I urge you to read it. I can't really to it justice in a short excerpt here. “Our entire society is perfectly designed to create Type 2 diabetes,” said Dr. Dean Schillinger, a professor of medicine at University of California, San Francisco. “We have to disrupt that.” Dr. Schillinger and nearly two dozen other experts laid out a road-map for doing so earlier this year in a comprehensive national report to Congress on diabetes, the first of its kind since 1975. It calls for reframing the epidemic as a social, economic and environmental problem, and offers a series of detailed fixes, ranging from improving access to healthy food and clean water to rethinking the designs of communities, housing and transportation networks. https://www.nytimes.com/2022/10/05/health/diabetes-prevention-diet.html XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX The Diabetes Design initiative is looking for college age people with type 1 to help them design the ultimate alarm for an extreme low. I'll put the contact info in the show notes, along with a link to the website. By the way, I had never heard of the Diabetes Design Initiative but boy do I know these names and you probably do too. Ben West, Dana Lewis and a few others from the history of we are not waiting http://ddi.ucsd.edu/about.html Grace Zheng gzheng@ucsd.edu XX On the podcast next week.. teens and type 1 – a deep dive into why teen retreats work from the people who organize a great one.. and how adults with type 1 still use the lessons they learned as teens. This past episode is all about Dexcom design. Listen wherever you get your podcasts Hey for you parents, we've got a webinar on Halloween, link in the show notes and on my social media. That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
(0:00) Welcome Rashad(1:20) Ghostwriting tweets(16:18) Mark Cuban backstory(17:24) Introducing Mark Cuban(18:23) When Bill Gates stole Mark's girl(19:24) Making his email public(20:49) Mark's superpower(22:29) Advice for young entrepreneurs(25:52) Growing up in Pittsburgh(30:27) Owning the sales process(35:18) Mark's journey(41:10) Retiring at 30(44:00) Broadcast.com(47:50) Recognizing the internet bubble(50:25) Crypto and early Internet parallels(58:28) Buying the Mavericks(1:02:50) Create your own narrative(1:06:08) Fame(1:08:37) Cost Plus Drugs(1:26:30) Rapid fire questions(1:31:25) Problem with the SEC(1:40:24) Outro Mixed and edited: Justin HrabovskyProduced: Andrew Nadeau and Rashad AssirExecutive Producer: Josh MachizMusic: Griff Lawson
HealthCast segment about Mark Cuban an dhow he is perhaps leaving Shark Tank to take his venture Cost Plus Drugs to the next level. Mark Cuban is cutting out the PBM and other middemen to bring low costs diabetes drugs, statins, and mental health drugs to market at a fraction of the traditional costs. Lance pontificates on his experience managing formulary at a health plan and how the costs for basic drugs are crippling citizens.
Class 4 Hurricane Ian lands in Florida, Kevin Matthew Kelp (Michael Kosta) investigates a nefarious ice cream truck conspiracy, and Mark Cuban discusses "Shark Tank" and Cost Plus Drugs.See omnystudio.com/listener for privacy information.
Celebrity entrepreneur Mark Cuban wants to make buying drugs less complicated and more affordable, and an online pharmacy he recently invested in aims to do just that. So how does this work, and is it enough to solve the drug pricing problem in America? Host Rachel (Rae) Woods talks with pharmacy experts Gina Lohr and Chloe Bakst about this business model and drug pricing reforms in the recently passed Inflation Reduction Act. Links: Can Mark Cuban lower Medicare drug costs? A deeper dive into the headlines Could cost plus drug pricing save Medicare billions? Ep. 131: Health care disruptors: Why Walgreens wants to partner—not compete
S1E41: On this episode, Don't Hit the “Easy” Button with Zack Robinson, CEO of DiscloseRx and host Dr. Nick. Drugs remain a major challenge for anyone needing medication for anything. The recent launch of Cost Plus Drugs is completely transparent on cost of their drugs and is trying to disrupt the pharmacy systems and in particular the pharmacy benefit managers. So with an extended moratorium on exposing the details behind all the schemes, refunds, kickbacks, and rebates, we are still a long way from full disclosure on pricing. While we are all hoping to be able to push the iconic “Easy” button, this is proving to be the worst possible choice. Because of the cloak of complexity, gag orders and the wide variety of ways that the flow of funds is hidden the onus is on all of us to take the harder less well-traveled path to more affordable and reasonable pricing of drugs. Your better pill to swallow is to accept that the bundled offerings are not in your best interest. They are not serving your business; they are not serving your employees or patients and there is a better way. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen
Mark Cuban is Mark Cuban: an entrepreneur's entrepreneur, Shark on Shark Tank, multi-billionaire, and investor. It would be shocking if you didn't know him. If you are that small minority you'll have to let us know how that goes. For all others, Mark is how you'd expect: charming, quick, and knowledgeable. Emphasizing one of his newer ventures with Cost Plus Drugs that is completely disrupting the pharmaceutical industry to sell generic drugs at a fraction of their current cost, taking detours to rave about Alyssa's Cookies, and jumping from topic to topic throughout his long career, Mark isn't shy about what's worked and what hasn't. Making his email public and admitting to basically scrolling it like it were social media, investing $100 million in people he's never met, Mark remains a risk-taking juggernaut "doing the work," researching, and asking the right questions to get what he wants. This one's definitely worth a listen! C'mon, it's Mark Cuban.Youtube Link to This EpisodeMark's Newest Venture "Cost Plus Drugs" - https://costplusdrugs.com/Mark's Twitter - https://twitter.com/mcuban
Mark Cuban, empresario multimillonario estadounidense, habló en La W sobre el lanzamiento de su farmacia online “Cost Plus Drugs” con medicamentos a precios bajos.
Steam Deck review Virtual Land and CityDAO CostPlus Drugs What's App, iOS, Android Insurance
Sometimes destiny is on your side. While at Summer League, the guys ran into Mark Cuban at dinner and thirty minutes later they were in the studio recording. Mark joins the pod to discuss shaking up the healthcare system with Cost Plus Drugs, how the company started and how they are changing the game. He also talks about Shark Tank, best & worst deals he has made, and how the show works behind the scenes. Of course the guys have to talk a little basketball as well, like why Mark bought the Mavs, how much he will spend on the away team's locker room, and the most impressive players he has seen since being an owner. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Today, we have two interviews with founders innovating in the US prescription drug market to bring prices down for consumers. First up, Molly talks with Alex Oshmyansky, CEO of The Mark Cuban Cost Plus Drug Company, about building a "parallel supply chain", the importance of transparency, and a breakdown of the "financial engineering" in the industry. (3:22) Then, she talks to Capital RX CEO AJ Loiacono for a full breakdown on PBMs (pharmacy benefit managers) and the opaque pharmaceutical supply chain. (40:35) (0:00) Molly intros today's two interviews (3:22) Mark Cuban Cost Plus Drugs Company CEO and Founder Alex Oshmyansky on operating a startup while still being a practicing doctor and Cost Plug Drugs' business model (11:21) Harmonic - Get $4000 off at https://harmonic.ai/twist (12:43) Alex explains the state of the US drug space, why they're trying to build a "parallel supply chain", the importance of transparency, and the origin story of the company (23:44) Prometheus - Go to https://prometheusalts.com or download it on the App Store and use the access code TWIST to sign up (25:11) Drug production, hot button drug issues (32:16) Alex explains the "financial engineering" and profiteering in the prescription drug space (39:15) BairesDev - Go to https://baires.dev/twist and get $10,000 off when you sign your first contract (40:35) Molly intros the next guest: Capital RX CEO AJ Loiacono, who explains the convoluted and opaque pharmaceutical supply chain (54:30) Understanding PBMs (pharmacy benefit managers) and the broader healthcare industry (1:04:09) AJ gets into his background, starting Capital RX, and how it fits into the ecosystem
A frequent listener asked me to take a look at a program to help save on the cost of prescription drugs. Join me as I take a look at the Mark Cuban Cost Plus Drugs program.
Reporter from The Reason Emma Camp joins First Up to chat about Dallas Mavericks owner Mark Cuban's endeavours in the pharmaceutical industry launching Cost Plus Drugs, focused on the wholesale, manufacturing and pharmacy distribution. Camp discusses Cuban's business landscape and the distribution of medication in the United States.
Wooo! We talk about a few current events on this episode. A female Israeli journalist was killed under controversial circumstances. A mysterious moon crater believed to be formed from a rocket body of some kind has scientists baffled. We discuss Marc Cuban's CostPlus drug company and what it's all about. And we discuss whether or not it was cool for a dude in Europe to ditch his job after being paid nearly thirty years of salary all at once. Join us! follow us on twitter, Gettr and Instagram, and youtube. @illuminatitele Click on these bands and listen to our projects or come to a show. Death of Skepsis Golgothan (Spotify) Golgothan (BandCamp) Alfred and the Teddinators CoolDill Metamorphicon Dillon Crozier --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/theskepsistelegraph/message Support this podcast: https://anchor.fm/theskepsistelegraph/support
In this DaVinci Innovators+ episode Dr. Maxwell Cooper interviews Mark Cuban, a serial entrepreneur, Owner of the Dallas Mavericks NBA Team, a Shark on ABC's Shark Tank Series, and Co-Founder of Mark Cuban Cost Plus Drugs. Mark outlines how Cost Plus Drugs is obtaining medications directly from manufacturers and wholesalers to provide medications at the lowest prices possible in the most transparent way. He also describes how physicians can easily send prescriptions to CostPlusDrugs.com and how patients can sign up. Mark tells the story of how his Co-Founder, Dr. Alex Oshmyansky cold emailed him about starting Cost Plus Drugs. Lastly, Mark describes his experience working with physician-entrepreneurs and gives advice for physicians starting companies. +DaVinci Innovators is a series of episodes of The DaVinci Hour Podcast that feature physicians, inventors, and entrepreneurs working on innovative medical technology and building companies impacting healthcare. *Views expressed in this podcast are those of the individuals, not their respective institutions Mark Cuban Cost Plus Drug Company Website: https://costplusdrugs.com/ Twitter: @costplusdrugs Instagram: @costplusdrugs The DaVinci Hour Podcast Website: https://www.dviacademy.com/the-davinci-hour DaVinci Academy Website: https://www.dviacademy.com/ 20% off Discount Code (TDH20) for DaVinci Academy's online video courses for Anatomy, Histology, and Biochemistry available at https://www.dviacademy.com/store YouTube: https://www.youtube.com/c/DaVinciAcademyMed/ Twitter: https://twitter.com/DviAcademy Instagram: https://www.instagram.com/davinci_academy1/ Facebook: https://www.facebook.com/dviacademy LinkedIn: https://www.linkedin.com/company/davinci-academy---dviacademy.com
People searching for cheaper alternatives to high priced prescription drugs have a new and perhaps unexpected option. It's an online pharmacy founded by Mark Cuban, a billionaire businessman, Shark Tank star and owner of the Dallas Mavericks. His new direct-to-consumer company, Cost Plus Drugs, offers more than 100 generic medications at discounted prices. He joins Geoff Bennett to discuss. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders
People searching for cheaper alternatives to high priced prescription drugs have a new and perhaps unexpected option. It's an online pharmacy founded by Mark Cuban, a billionaire businessman, Shark Tank star and owner of the Dallas Mavericks. His new direct-to-consumer company, Cost Plus Drugs, offers more than 100 generic medications at discounted prices. He joins Geoff Bennett to discuss. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders
Speaking Of Show - Making Healthcare Work for You & Founder's Mission Series
In this in-depth interview with Mark Cuban, he shares how his new company, Cost Plus Drugs, is on a mission to disrupt the prescription drug industry. By charging a nominal 15% mark-up by eliminating the middle man, he and his team are making drugs affordable for everyone.
April 8, 2022: Our guest today is https://www.linkedin.com/in/mark-cuban-06a0755b/ (Mark Cuban), American billionaire entrepreneur, television personality, media proprietor and the Founder of the https://costplusdrugs.com/ (Mark Cuban Cost Plus Drug Co). The drug industry is up against giant companies with lots of money and influence and complicated relationships with tentacles wrapped around government manufacturers, insurance companies, drug stores, pharmacists, retailers and more. There's all kinds of super complicated contract arrangements that include rebates and hardwired incentives that keep this giant self-licking ice cream cone stuck together. The participants in this cartel like the deals they have and they make good money on them. The system is built to keep others out. But every American should have access to safe, affordable medicines. How is the https://costplusdrugs.com/ (Mark Cuban Cost Plus Drug Co) disrupting this space? Key Points: We have one simple goal. To be the lowest cost provider of drugs. Period. End of story. Patients want cheaper drugs. It makes their life easier. A red flag in the cost of healthcare in the US is the administrative costs https://costplusdrugs.com/ (Mark Cuban Cost Plus Drug Co) Mark Cuban's email: mcuban@gmail.com
Some people are natural born leaders, entrepreneurs, innovators, free thinkers - even fewer are all of those things and then some. The one and only Mark Cuban shares his honest and unfiltered thoughts with Kasich & Klepper on the issues of big pharmacy, insurance, and banking. He also predicts the future of artificial intelligence, cryptocurrency, and why too much power and influence in the hands of Mark Zuckerberg scares him. To learn more about The Mark Cuban Cost Plus Drug Company and how Cost Plus Drugs works, go to costplusdrugs.com See acast.com/privacy for privacy and opt-out information.
What will Cost Plus Drugs mean for your pharmacy? What New Challenges does it bring and what opportunities does it present? And then what do you do about it? Join us for a discussion on the impact of of Cost Plus Drugs on retail pharmacy with Hartig Drug CEO Charlie Hartig. Learn more about your ad choices. Visit megaphone.fm/adchoices
What will Cost Plus Drugs mean for your pharmacy? What New Challenges does it bring and what opportunities does it present? And then what do you do about it? Join us for a discussion on the impact of of Cost Plus Drugs on retail pharmacy with Hartig Drug CEO Charlie Hartig. Learn more about your ad choices. Visit megaphone.fm/adchoices
Today in the club we highlight Mark Cuban's newest venture Cost Plus Drugs, literally adding a small margin onto the actual cost of pharmaceuticals. Ask yourself, what is the most-watched video ever on YouTube, if you read the title then you already know. Finally, we weigh in on how Elon Musk is destroying the moon! All that and more in the club. Mark Cuban is opening up an online pharmacy with ultimate price transparency https://vm.tiktok.com/TTPdhLfvSy/ https://costplusdrugs.com/ Ploywork is trying to redo what LinkedIn could've been: https://www.crunchbase.com/organization/polywork raised 16.5 million without any super-advanced stuff Elon Musk will end humanity - SpaceX rocket to hit the moon, 27,000 other pieces of space garbage floats around just fine. https://www.livescience.com/spacex-rocket-to-hit-moon Death tech: what happens to your digital life after you're gone? https://mygoodtrust.com/ Graze - https://waxinvest.com/ A Fully Autonomous Commercial Lawn Mower Disrupting a $100B Market
If you take prescription medication, Mark Cuban is about to save you money. He is determined to upend the industry! So far, he's well on his way. Get ready to pay less... much less for your prescriptions.The pharmaceutical industry is nearly $600 billion a year! It actually could be much more! Most of it is waste and corruption. Unfortunately, the American people are force to pay the bill. Some drugs sell for hundreds, yet are made for pennies. Why? Well, Mark is going to tell you why. This discussion is only the beginning. On his website www.costplusdrugs.com he says, "We started Mark Cuban Cost Plus Drug Company because every American should have access to safe, affordable medicines. If you don't have insurance or have a high deductible plan, you know that even the most basic medications can cost a fortune. Many people are spending crazy amounts of money each month just to stay healthy. No American should have to suffer or worse - because they can't afford basic prescription medications. If you are fortunate enough to have health insurance with a low deductible, the high cost of drugs is driving up the premiums that you or your employer pay, making getting health insurance expensive and challenging.The Mark Cuban Cost Plus Drug Company takes these problems head on." Mark discusses this and more on the podcast.
The Twenty Minute VC: Venture Capital | Startup Funding | The Pitch
Mark Cuban is a serial entrepreneur, investor, and owner of the Dallas Mavericks. Today we are focused on Mark's latest entrepreneurial endeavor, starting Mark Cuban's Cost Plus Drug Company, the online pharmacy taking out the middlemen, meaning no price games and huge drug savings. As mentioned, Mark is also the proud owner of Dallas Mavericks, since his taking over they have competed in the NBA Finals for the first time in franchise history in 2006 – and became NBA World Champions in 2011. Before Dallas Mavericks, Mark co-founded Broadcast.com – streaming audio over the internet. In just four short years, Broadcast.com (then Audionet) was sold to Yahoo for $5.6 billion dollars. If that was not enough, Mark is also one of ABC's “Sharks” on the hit show Shark Tank. In Today's Episode with Mark Cuban You Will Learn: 1.) Cost Plus Drugs: Origin Why Mark decided to build Cost Plus Drugs? Why has no one done it before? How does Mark think about resource and time allocation with Cost Plus? 2.) Building the Team: Hiring How does mark analyze his approach to hiring? Where is he weak? Where is he strong? What one motto does Mark always use when it comes to hiring? What is the most common mistake Mark sees founders make when it comes to team build? How does Mark identify stress removers? What are the core signals? 3.) Brand + Capital + Business Strategy: Why is the current cost structure of healthcare so damaged in the US? How does Cost Plus change this? How does Mark think about what it takes to build great brand today? Why will Cost Plus not be doing big TV and traditional media advertising? What types of guerilla marketing is Mark most excited by? Why will Mark never have a billboard in Times Square? 4.) AMA with Mark Cuban: What 3 traits does Mark most want his children to adopt? What worries Mark most today? What are Mark's biggest strengths? What are his biggest weaknesses? What single purchase has brought Mark the greatest joy?
The None of our Businesses crew gather to discuss Mark Cuban's affordable pharmaceuticle company, the controversial CEO who fired 900 employees over zoom resumes duties, accounting tips for dealing with cryptocurrency, El Salvador has invested millions in bitcoin while adopting it as legal currency, and the IRS has agreed to dial back their automated penalty notices. Cost Plus Drugs - https://www.forbes.com/sites/lisakim/2022/01/20/billionaire-mark-cuban-opens-online-pharmacy-to-provide-affordable-generic-drugs/?sh=31893113e4a3 Better CEO - https://www.nbcnews.com/business/business-news/ceo-laid-900-workers-zoom-returns-break-duties-rcna12772 Cryptoasset Accounting - https://www.journalofaccountancy.com/news/2022/jan/cryptoasset-accounting-tips-common-scenarios.html Crypto in El Salvador - https://www.forbes.com/sites/zacharysmith/2022/01/21/el-salvador-buys-15-million-worth-of-bitcoin-really-cheap-president-crows-as-selloff-continues/?sh=3dc0017860ed IRS Notices - https://www.accountingtoday.com/news/irs-agrees-to-ease-automated-penalty-notices None of Our Businesses Episode 108, February 2022
This week, Mr. Mime can strangle you to death in the woods, be careful when using your Dr. Sue inserts, are we lizard enough to fall in love with a robot head, and crashing a plane into a magic forest has to sting! Come join the Backyard Bonanza in our Discord!https://discord.gg/QND8pNasHAWe have merch now?! Come get some!https://best-friends-tiny-inc.creator-spring.com/Malcolm's Cream (Guest Podcast Promo):Malcolm was on vacation this week, but he sure does love Homicide Worldwide, Pick Me!, Haunt Her? I Barely Know Her!, NightmareTown, Anime Talk!, and The Grapevine Cowboy, Kevin Busby!Theme Music:Jeremy Blake - Powerup!Technical Difficulty Music:Kevin Macleod - Local ForecastNerd stuff and farts from this episode:Pokemon, Pokemon Arceus, Elden Ring, Snorlax, Pokemon Go, Mark Cuban, Cost Plus Drugs, Talkin Sex with Sue, Sex Talk, Lexx, Yellow Jackets, LOSTSupport the show (https://www.patreon.com/bestfriendstinyinc)
RxSafe & ApproRx have sponsored a gathering of 200+ pharmacy owners interested in learning more about a drug manufacturer interested in working directly with Pharmacy owners. Thanks to Bruce Kneeland and Todd Eury for hosting this LIVE presentation from March 2nd 2021. Today was the 12th anniversary of the Pharmacy Podcast Network. The 1st podcast about the profession of pharmacy launched episode 1 on March 2nd 2009. Today the PPN has 30+ hosts & is dedicated to the success of our pharmacists & pharmacy techs. Alex Oshmyansky, MD, PhD is the CEO & Founder at Mark Cuban Cost Plus Drug Company. Dr. Alex along with strategic investor & business mogul Mark Cuban has launched Mark Cuban Cost Plus Drug Company, a pharmaceutical company that plans to make less expensive versions of selected generic drugs. The company's first drug is a generic version of albendazole, an antiparasitic drug used to treat hookworm. Treated early, two tablets will treat the infection; left untreated, cognitive defects and neurological problems can result. Cost Plus Drug Company is dedicated to producing low-cost versions of high-cost generic drugs. In this interview, Dr. Alex pledges to provide radical transparency in how they price their drugs. Dr. Alex has committed letting everyone know what it costs to manufacture, distribute, and market drugs to pharmacies. They will add a flat 15% margin to get wholesale prices. This will help to ensure they remain viable and profitable. There are no hidden costs, no middlemen, no rebates only available to insurance companies. Everybody gets the same low price for every drug they make. The Pharmacy Podcast Network is the global leader in podcast content for the Business & Profession of Pharmacy. Since March 2009, the Pharmacy Podcast was the first audio blog for the pharmacy industry and has developed into a directory of over 25+ podcasts with different vertical informational themes. Collectively, over 2.5M downloads, more than 2,000+ episodes, and 30+ participating Pharmacists and Pharmacy Professionals hosting the podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices
RxSafe & ApproRx have sponsored a gathering of 200+ pharmacy owners interested in learning more about a drug manufacturer interested in working directly with Pharmacy owners. Thanks to Bruce Kneeland and Todd Eury for hosting this LIVE presentation from March 2nd 2021. Today was the 12th anniversary of the Pharmacy Podcast Network. The 1st podcast about the profession of pharmacy launched episode 1 on March 2nd 2009. Today the PPN has 30+ hosts & is dedicated to the success of our pharmacists & pharmacy techs. Alex Oshmyansky, MD, PhD is the CEO & Founder at Mark Cuban Cost Plus Drug Company. Dr. Alex along with strategic investor & business mogul Mark Cuban has launched Mark Cuban Cost Plus Drug Company, a pharmaceutical company that plans to make less expensive versions of selected generic drugs. The company's first drug is a generic version of albendazole, an antiparasitic drug used to treat hookworm. Treated early, two tablets will treat the infection; left untreated, cognitive defects and neurological problems can result. Cost Plus Drug Company is dedicated to producing low-cost versions of high-cost generic drugs. In this interview, Dr. Alex pledges to provide radical transparency in how they price their drugs. Dr. Alex has committed letting everyone know what it costs to manufacture, distribute, and market drugs to pharmacies. They will add a flat 15% margin to get wholesale prices. This will help to ensure they remain viable and profitable. There are no hidden costs, no middlemen, no rebates only available to insurance companies. Everybody gets the same low price for every drug they make. The Pharmacy Podcast Network is the global leader in podcast content for the Business & Profession of Pharmacy. Since March 2009, the Pharmacy Podcast was the first audio blog for the pharmacy industry and has developed into a directory of over 25+ podcasts with different vertical informational themes. Collectively, over 2.5M downloads, more than 2,000+ episodes, and 30+ participating Pharmacists and Pharmacy Professionals hosting the podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices
The new podcast called “Decoder with Nilay Patel” episode 1 @reckless released on Nov 10, 2020 with special guest MARK CUBAN ON AMERICA'S FUTURE & a short clip about Cost Plus Drugs. Alex Oshmyansky, MD, PhD is the CEO & Founder at Mark Cuban Cost Plus Drug Company. Dr. Alex along with strategic investor & business mogul Mark Cuban has launched Mark Cuban Cost Plus Drug Company, a pharmaceutical company that plans to make less expensive versions of selected generic drugs. The company's first drug is a generic version of albendazole, an antiparasitic drug used to treat hookworm. Treated early, two tablets will treat the infection; left untreated, cognitive defects and neurological problems can result. Cost Plus Drug Company is dedicated to producing low-cost versions of high-cost generic drugs. In this interview, Dr. Alex pledges to provide radical transparency in how they price their drugs. Dr. Alex has committed letting everyone know what it costs to manufacture, distribute, and market drugs to pharmacies. They will add a flat 15% margin to get wholesale prices. This will help to ensure they remain viable and profitable. There are no hidden costs, no middlemen, no rebates only available to insurance companies. Everybody gets the same low price for every drug they make. See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices
© 2020-2025 Ivy Podcast Discovery LLC
